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BACKGROUND:   
Breast cancer is the most commonly diagnosed cancer and second leading cancer death cause among 
females in the U.S.A. About 1 in 8 women in U.S will develop invasive breast cancer over the course of her 
lifetime. In 2013, 234,580 new invasive breast cancer cases are expected to occur in women within the US 
and approximately 64,640 non-invasive carcinomas in situ were diagnosed in 2013, most of which were 
ductal carcinoma in situ (DCIS). Along with technological advances, a wide variety of candidate 
biomarkers have been proposed for cancer diagnosis and prognosis, including DNA content and non-
coding RNA. Current techniques for detecting DNA content abnormalities in formalin-fixed, paraffin-
embedded (FFPE) tissue samples by flow cytometric analysis have used cells recovered from ≥50µm whole 
tissue sections. Here, in our first study, a novel core punch sampling method was investigated for assessing 
DNA content abnormalities and intratumoral heterogeneity in FFPE specimens. Secondly, long non-coding 
RNAs (lncRNAs) has been examined. LncRNA participates in a broad spectrum of biological activities by 
diverse mechanisms and its dysregulation is associated with tumorgenesis. Some lncRNAs may function as 
oncogenes (O) and others as tumor suppressor genes (TSG). To date, lncRNA has been investigated 
primarily by qRT-PCR and RNA sequencing. This study has examined the relationship of lncRNA 
expression patterns to breast tumor pathology by chromogenic in situ hybridization (CISH).  
METHODS:  
Firstly, FFPE breast carcinoma specimens were selectively targeted using 1.0 mm diameter punch needles. 
Extracted cores were assayed by flow cytometry using a modified-Headley method. Secondly, the lncRNA 
expression levels of 6 lncRNAs: HOTAIR, H19, KCNQ1OT1, MEG3, MALAT11 and Zfas1, was 
examined by RNAscope® CISH using FFPE breast tissue microarrays (TMAs) comprising normal adjacent 
epithelia (NA), DCIS, and invasive carcinoma (IC) from 46 patients. LncRNA associate polycomb 
complex protein EZH2 was evaluated by immunohistochemistry (IHC). LncRNA data was also compared 
to standard breast tumor data including ER, PR, Her2 and Ki67 IHC. SYSTAT version 11 statistical 
package was used to perform for all the tests.  
RESULTS: 
Following optimization experiments of the core punch flow cytometric approach, DNA index and percent 
S-phase fraction intratumoral heterogeneities were detected in 10/23 (44%) and 11/23 (47%) specimens 
respectively. The lncRNA CISH study utilized a TMA that contained 36 spots of NA breast tissues, 34 
DCIS spots and 43 IC spots. HOTAIR CISH staining was significantly stronger in IC than DCIS (p<0.001) 
and NA spots (p<0.001). In DCIS, HOTAIR was correlated with Her2 (p=0.03) IHC. And in IC, the data 
suggest HOTAIR is a marker for high histological grade (p=0.026). H19 was rarely expressed in normal 
adjacent epithelial or tumor cells but was strongly expressed especially in inter-lobular stromal cells around 
invasive growths (p<0.001). H19 correlated with Ki67 IHC expression in DCIS, (p=0.047). KCNQ1OT1 
expressed stronger in IC and DCIS than in NA (p<0.001), and was associated with Her2 (p= 0.032) in IC. 
No significant expressional difference was found in MEG3. MALAT1 stained strong universally and Zfas1 
was very faint in all samples; as such neither of these was analyzed statistically. Polycomb protein EZH2 
expressed differently among tissues but did not correlate with lncRNA levels. 
CONCLUSION:  
Core-punching is an effective alternative to whole specimen sectioning and shows that macro-level 
genomic heterogeneity is common even within a single FFPE block. The interrelationship of DNA content 
heterogeneity to other forms of heterogeneity requires further study. RNAscope CISH supports bright-field 
microscopy investigations of lncRNA expression in FFPE tissue specimens. HOTAIR, H19 and 
KCNQ1OT1 may be potential breast cancer biomarkers, both HOTAIR and H19 may be a marker for DCIS 
at increased risk of progression to invasive cancer. HOTAIR, in particular, may be a predictor for invasive 
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Comprehensive Literature Review 
 
Introduction 
Breast cancer is the most commonly diagnosed cancer and second leading cause of cancer death 
among females in the U.S (CDC website). In 2013, 234,580 new invasive breast cancer cases are 
estimated to occur in women in U.S, whereas 2,240 cases are expected in men (Siegel, 
Naishadham et al. 2013). In addition to invasive breast cancer, around 64,640 new cases of non-
invasive carcinoma in situ in women breast, most of which are ductal carcinoma in situ (DCIS), 
are predicted to be newly diagnosed in 2013 (Siegel, Naishadham et al. 2013). About 14% female 
cancer deaths in 2013 are estimated to result from breast cancer (Siegel, Naishadham et al. 2013). 
With the advancement of classification systems, screening techniques and therapeutics, more and 
more females have been diagnosed with breast cancer at younger ages and have received better 
treatment. Breast cancer caused female deaths have decreased steadily since 1990, with a 
dramatic decrease in women aged 20-69 years old (Lacey, Devesa et al. 2002; Bray, McCarron et 
al. 2004). Rather than invasive breast carcinoma, which is able to metastasize to regional lymph 
nodes or distant sites, DCIS is confined within the basement membrane of ducts and lobules and 
often co-exists with invasive cancer cells; it can eventually develop to invasive cancer. The 
treatment for DCIS has become a widespread medical issue because of malignant uncertainty 
(Ernster and Barclay 1997; Duffy, Agbaje et al. 2005; Virnig, Tuttle et al. 2010) and most 
patients get treated with surgery, breast irradiation and endocrine therapy (Baxter, Virnig et al. 
2004), however, about 70% of DCIS have been found not to have a devastating impact on a 
patient’s life (Page, Dupont et al. 1982; Eusebi, Foschini et al. 1989; Eusebi, Feudale et al. 1994).  
Chromosomal instability (CIN), resulting from elevated rate of chromosome missegregation 
during mitosis, is a hallmark of cancer. DNA ploidy changes are one consequence of CIN and 
typically result in abnormal DNA content (Fridlyand, Snijders et al. 2006). Sporadic tumors likely 
2 
 
develop through processes involving chronic sub-clonal diversification and accumulation of 
genomic aberrations resulting in intratumoral heterogeneity, which is being unveiled by large-
scale massively parallel sequencing and paving the path for personalized medicine(Campbell, 
Pleasance et al. 2008; Campbell, Yachida et al. 2010; Michor and Polyak 2010).  
Long non-coding RNA (lncRNA), transcribed RNA molecules greater than 200 nucleotides in 
length, has been demonstrated to be involved in multiple biological activities including 
epigenetics regulation, transcriptional regulation, interaction with small non-coding RNA, post-
transcriptional regulation, nuclear compartment formation and cell cycle control (Gupta, Shah et 
al. 2010; Hung, Wang et al. 2011; Tsuiji, Yoshimoto et al. 2011; Schor, Lleres et al. 2012; Han, 
Liu et al. 2013; Luo, Li et al. 2013; Tripathi, Shen et al. 2013). Both DNA content abnormalities 
(Pinto, Monteiro et al. 2005; Bremmer, Brakenhoff et al. 2011) and lncRNAs (Dhanasekaran, 
Barrette et al. 2001; He, Bao et al. 2014; Zhao, Guo et al. 2014) have already been suggested as 
biomarkers in some cancer types, but this has not yet been investigated in DCIS. Understanding 
the potential role of CIN, intratumor heterogeneity and lncRNAs in breast tumor pathology would 
be valuable to science and medicine by creating better diagnostic methods, screening options and 
treatments. 
Breast cancer symptoms 
Early breast cancer doesn’t cause any significant symptoms, so regular breast test is required. 
Although patients are not able to notice a lump on breast, which is a very typical symptom for a 
breast tumor, people can still pay attention to subtle changes to the body to get some clues for 
early disease. These signs include subtle changes in breast size and shape, some morphological or 
color changes in skin, for example, dimpling, swelling or becoming red. As a tumor grows, 
apparent symptoms can be seen, including a breast lump or lump in the armpit that are hard and 
have uneven edges, more visible changes in breast size, shape, or a recent nipple change, as 
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example, nipple inversion, nipple ulceration, retraction, bloody discharge as well as peeling, 
However, more than 80% breast cancer case are detected by breast lump (Therapy 2003). When 
cancer advances, there are a more symptoms that can be noticed by both patients and clinicians. 
Bone pain, breast discomfort, skin ulcers, swelling of one arm and weight loss are important 
features at that stage. According to different presentations of breast cancer in different stages, a 
complete test that helps doctors determines the exact stage that is necessary. Physical exams 
include breasts, armpits, and the neck and chest area and a variety of methods are combined. For 
instance, magnetic resonance imaging (MRI) scan can provide clinicians with better identification 
of a breast lump or an abnormal mammogram changes, ultrasound can be utilized to show 
whether the lump is solid or not, and biopsies help pathologists to stage or come up with a 
treatment decision. Computerized tomography (CT) scans can contribute to analyzing the tumor 
spread. To test a very subtle change in breast contour, the test must contain one assessment of the 
breast with patients upright with arms raised. If some symptoms like contour change, skin 
tethering, dilated veins, ulceration, or Paget’s disease are found then clinicians become more 
concerned about the patient. Paget’s disease, whose symptoms include eczematoid skin, is 
diagnosed in almost a quarter of the female patients (NCI 2005). Additionally, tests on axillae and 
supraclavicular fossae areas and additional abdominal and neurologic examination should be 
included to make a complete evaluation because there might be some symptoms indicating 
metastasis occurring in such places. These symptoms include breathing difficulties, bone pain, 
symptoms of hypercalcemia, abdominal distention, jaundice, localizing neurologic signs, and 
altered cognitive function.  
Though a lump is an indicator for breast tumor, it is quite indiscernible and hard to detect 
inflammatory breast cancer, which can pose a substantial diagnostic challenge. For diagnostic 
purposes, people who may have this type of cancer should pay attention to symptoms that 
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resemble a breast inflammation as well as itching, pain, swelling, nipple inversion, warmth and 
redness throughout the breast. Moreover, peau d'orange, which is an orange-peel texture on skin 
could be another sign. Occasionally localized breast cancer cells metastasize to other locations 
through the body including bone, brain, liver and lung. Unexplained weight loss and fever 
sometimes presage occult breast cancer and pains in the bones or joints could also manifest 
metastatic breast cancer, however all these symptoms are non-specific, meaning they could also 
be indications of other diseases. 
Breast cancer histology features and classification 
The accurate diagnosis and pathological assessment are key steps undertaken by pathologists, 
who need to differentiate benign breast tissues from early and established breast cancers. Then, an 
evaluation of pathological features and suggestions for treatment should be provided by 
pathologists (Russo and Russo 1992). Carcinomas are most common malignant tumor types for 
breast tissues and can be divided into two groups: carcinoma in situ and invasive carcinoma. And 
since most breast carcinomas are derived from epithelium of ducts or lobules, we also define 
them as mammary ductal carcinoma and lobular carcinoma. By histopathological evaluation, the 
three most frequent carcinoma types are invasive ductal carcinoma (55%), DCIS (13%) and 
invasive lobular carcinoma (5%) comprising about approximately 75% of all incidence (Eheman, 
Shaw et al. 2009).  Invasive carcinoma usually presents with a large breast mass and sometimes 
with nipple discharges or breast pain. When observed by microscopy, invasive carcinoma is more 
fixed asymmetrically and not well circumscribed. However, nearly all triple negative tumors 
present solid architectures without forming tubules and have a large amount of tumor cells with 
little stromal area between these cells, demonstrating very detailed morphological difference. In 
addition, above half of basal-like tumors exhibit a pushing border and have stromal lymphocytic 
infiltration at the edge of tumor to some extent (Livasy, Karaca et al. 2006). DCIS, with the 
exception of neoplastic epithelial proliferation within the ducts basement membranes shares some 
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symptoms with invasive cancer and surprisingly, many similarities between DCIS cells and 
invasive carcinoma cells are found, on both cellular and molecular levels (Ma, Salunga et al. 2003; 
Hannemann, Velds et al. 2006; Kuerer, Albarracin et al. 2009).  
Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) are valuable tools for 
histological assessment to identify estrogen receptor (ER), progesterone receptor (PR) and human 
epidermal growth factor receptor 2 (Her2) expression status. Sentinel lymph node biopsy is 
another method to aid histological assess, especially for metastatic status (Veronesi, Paganelli et 
al. 1997).The nearest single lymph node to primary breast tumor is removed and examined in 
detail to see if there are some tiny clusters of metastatic cells. If no tumor cells are found, 
pathologists can predict a very low chance to get metastatic cells in axillary lymph nodes, and 
therefore, full lymph node excision is not necessary. The classification of the invasive breast 
cancer aims to classify breast cancers into various categories according to different criteria in 
order to primarily help select the best therapeutics and provide a better prognosis. In 2003, the 
World Health Organization recommended a comprehensive breast cancer classification system 
including both non-malignant and malignant tumors to help clinicians to better identify tumor 
types and specific treatments (Tavassoli, Devilee et al. 2003). Histopathology, tumor grade, 
tumor stage and receptor expression status are most commonly used criteria for classification. 
Tumor grade relies on the similarity and differences between cancer cells and normal cells and 
thus divides tumor into three major groups: low grade (well-differentiated), intermediate grade 
(moderately differentiated) and high grade (poorly differentiated). Usually well-differentiated 
tumor has a better prognosis due to its similar appearance as normal cells. The overall grade is 
assessed by the Nottingham system (Genestie, Zafrani et al. 1998; Simpson, Gray et al. 2000), 
which generates the overall scores by totalizing scores for nuclear features, tubule formation and 
mitotic activity, each of which is scored from 1 to 3 points. Nuclear feature is used to assess how 
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much variation tumor cell nuclei have compared with normal breast cells nuclei, while tubule 
formation is a parameter that evaluates how much tumor has the normal structure of ducts. 
Uncontrolled cell division is one of the hallmarks of cancer, so mitotic count is a parameter to 
assess how many dividing cells can be seen in 10x microscope fields.  The sum of three points 
can lead to a conclusion: 3-5 points means grade 1 tumor which is the best among the three, 6-7 
represents grade 2 tumor and 8-9 points is grade 3 tumor. Tumor stage is a criterion which 
determines how severe the cancer is and often come along with estrogen/ progesterone receptor 
expression levels, Her2 status and menopausal status for a diagnostic decision. At present, the 
tumor, nodes and metastases (TNM) staging system is the most widely used in world. Tumor 
value is based on the primary cancer and lymph node value depends on cell number, size in 
regional lymph nodes, and metastases value refers to the information of metastatic cancer. Both 
grade and staging units contribute to The Nottingham Prognostic Index (NPI) (Galea, Blamey et 
al. 1992). NPI= (0.2 x tumor size (cm)) + tumor grade + stage, is an equation to stratify patients 
into different prognostic group, due to which, favorable prognosis has scores below 3.4 and 
medium gets scores between 3.41 to 5.4. However, poor prognosis has a score greater than 5.41 
(Galea, Blamey et al. 1992).  
IHC and FISH tests for ER, PR, and Her2 are the most common methods to help classify breast 
cancers and of great importance as a guide for therapeutics. Based on different receptor 
expression, most breast cancers are categorized to five groups including luminal A/B, Her2+, 
triple-negative Claudin-low and normal basal-like (Perou, Sorlie et al. 2000). Estrogen receptor 
positive (ER+) cancer cells can be treated with tamoxifen (Jordan and Koerner 1975) or 
aromatase inhibitors (AIs) (Smith and Dowsett 2003)to reduce estrogen effect or decrease ER 
expression level because these cells need estrogen to grow, while monoclonal antibody 
trastuzumab can precisely target Her2 positive cancer cells and thus highly improve breast cancer 
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therapeutics combining with traditional chemotherapy (Romond, Perez et al. 2005).  In terms of 
DCIS, the current pre-mammography classification is predominately relied on microscopic 
features: comedo, solid, papillary, micropapillary and cribriform (Allred 2010).  The grading 
system refers to the degree DCIS cells resemble normal cells, the level DCIS cells differentiate, 
conveying criteria from existing invasive breast cancer histology grading pattern since we know a 
positive relationship between tumor cell differentiation and cancer aggressiveness (Elston and 
Ellis 1993). 
Genetics 
BRCA1 and BRCA2 are most important hereditary genes in breast cancer genetics. More than 
200 germline mutations in BRCA1 and over 100 mutations in BRCA2 shows clear associations 
with breast cancer susceptibility and have been registered in the Breast Cancer Information Core 
Database (Szabo, Masiello et al. 2000). Mutations of BRCA1 and BRCA2 have been reported to 
account for almost 20-25% familial breast cancer cases but less than 10% of overall breast 
cancers. The majority of known mutations in BRCA1 and BRCA2 are predicted to result in 
premature translation termination (Easton 1999). BRCA1 encodes a 220kD nuclear protein and 
its molecular functions are to control cell cycle (i.e., functional BRCA1 missing will cause cell 
cycle arrest) and responses to DNA damage (Gowen, Avrutskaya et al. 1998; Scully and 
Livingston 2000). In the meantime, BRCA1 is also a component of the RAD51-MRE11-p95 
complex that works for DNA repair system (Scully, Chen et al. 1997). BRCA2 encodes a bigger 
protein which also involves in DNA double-strand break repair and maintains chromosome 
integrity (Chen, Silver et al. 1999). Approximately 15-20% women have been found with BRCA1 
mutation if someone had breast cancer in their family history and the number is 60-80% when 
their families showed both breast and ovarian cancer (Couch, DeShano et al. 1997). These 
mutations carriers have a chance of 60-80% to get breast cancer through their lifetime, with a 
median diagnosed age of 20 years as compared to those women who do not have BRCA1 
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mutations (Easton, Narod et al. 1994; Struewing, Tarone et al. 1996). Females who carry BRCA2 
mutation will also have 60-80% chance to get cancer eventually, while men with BRCA2 
mutations will surprisingly develop a 6% lifetime breast cancer risk.  It has been found those 
BRCA associated cancers appears in patients’ at younger ages and are more dangerous. BRCA1 
mutations have been shown to associate with triple negative breast cancer (TNBC), while 
mutations in BRCA2 are more likely to be found in post-menopausal breast cancer.  
Scientists have also found several germline genetic mutations that contribute to breast cancer risk 
by analyzing familial data, including STK11/LKB1, phosphatase and tensin homolog (PTEN), 
androgen receptor (AR) and p53 (Malkin, Li et al. 1990; Wooster, Mangion et al. 1992; Liaw, 
Marsh et al. 1997; Boardman, Thibodeau et al. 1998). However, all these genetic factors 
mentioned above are rarely found across the population so that they can only account for a very 
small portion of heritability of human breast cancer. As techniques develop, the secrets of breast 
cancer genetic world are rapidly getting dissected. With comparative genomic hybridization 
(CGH), patterns of chromosome gain and loss have characterized breast cancer of different grades 
(Roylance, Gorman et al. 1999). Losses of 11q, 8p, 13q, gains on 1q, 8q, 17q are high grade 
invasive breast tumor signatures whereas low grade cancers commonly show gains on 1q, 16p, 8q 
and loses of 16q (Buerger, Otterbach et al. 1999; Roylance, Gorman et al. 1999). Noticeably, 
DCIS shows high similarities to genetic abnormalities found in invasive cancers (Buerger, 
Otterbach et al. 1999). Advanced high-throughput sequencing have identified many susceptible 
loci in candidate genes, single nucleotide polymorphisms (SNP) and copy number variations 
(CNV) in somatic cells that are highly associated with breast cancer.  MAP3K1, AKT2 and 
CDKN1B are newly found genes that contribute to breast cancer susceptibility (Stephens, Tarpey 
et al. 2012).  Together with meta-analysis, results from different genome–wide association studies 
can by synthesized to better identify some widely-accepted loci in different race, e.g., 6q14 and 




Screening for breast cancer is for apparent healthy women to get an early diagnosis, which will 
largely improve the final outcomes. Several tests have been utilized including self and clinical 
breast exams, mammography, genetic screening, MRI and ultrasound. In 2003, a review 
demonstrated that breast cancer examination did not associate with lower death rates and so did 
not recommend self or clinical exams (Kosters and Gotzsche 2003).  Mammography utilizes a 
specialized X-ray machine which emits a small amount of ionizing radiation to get the X-ray 
image, which will be on plain digital mammography or photographic film on a computer screen, 
interpreted by radiologists and now it becomes a very common breast cancer screening test 
among women ages 40 to 74 because of its quickness and wide availability (Mandelblatt, Cronin 
et al. 2009). Overall, mammography saves a small number of lives and is more effective in older 
aged women but it has no benefits for predicting the outcome of that cancer. Recommendations 
about what time and what frequency it is best to undergo mammography screening vary across 
the world. Although mammography offers a small, but statistically significant benefit, it also 
creates some criticism because many patients overestimate the effect that mammography provides 
and this often results in heavy psychological and financial burden. MRI is another tool in 
screening breast cancer with a very high negative predictive value and it can also diagnose benign 
proliferative changes, fibroadenomas and some other benign findings. In terms of shortcomings, 
it is much less specific than mammography, more expensive and less available in some 
developing countries. The third screening method is genetic test, which can only reveal a 
susceptibility to develop cancer rather than detect cancer. Due to significant role of BRCA 
mutation in promoting breast cancer, US government published a clinical practice guideline to 
recommend women for BRCA mutation test (Nelson, Huffman et al. 2005). About 2% of 
American women have family histories have been found with an increased risk of having a 




The mainstay of breast cancer treatment is surgery if the tumor is localized and the following 
treatments are chemotherapy, radiotherapy and hormonal therapy. There is no general treatment 
for all kinds of breast cancer so it is very important to identify what specific molecular subtype 
the patient has beforehand. TNBC has been given first priority currently by clinicians around the 
world because it has the worst prognosis among all breast cancer subtypes. Multiple clinical trials 
have been tried on TNBC patients and it has already been found that several chemotherapeutic 
drugs and biological agents are very promising. DNA-damaging compounds like platinate agents 
should be useful because platinum compounds function in developing a covalent bifunctional 
cross-linked adducts, which blocks DNA double-strand break caused by replication forks 
(Helleday, Petermann et al. 2008; Bosch, Eroles et al. 2010).  Epidermal growth factor receptor 
(EGFR) is another therapeutic target because it is expressed in 45-70% TNBC cases, but target 
antibody or drugs including Cetuximab still await assessment (O'Shaughnessy 2007). 
Angiogenesis is critical for tumor growth so drugs that specifically target neoangiogenesis is 
another treatment option. Bevacizumab was approved by FDA to treat metastatic Her2-negative 
breast cancer in combination with paclitaxel due to results of the phase III clinical trial E2100 
(Miller, Wang et al. 2007).  Another clinical trial that tested Bevacizumab detected a statistically 
significant difference in progression-free survival between women taking bevacizumab and 
docetaxel (Miles D 2008) .Last but not at least, PARP inhibitors are compounds that work to 
inhibit already defective DNA repair, which could be potentially used.  
Lumina A type, which is a low grade breast cancer that is ER-positive and Her2-negative, has the 
best prognosis among all the subgroups. It seems there is no standard treatment for luminal A and 
it depends on an individual’s traits, tumor size, histological grade and lymph node conditions. 
Luminal B type is a higher grade breast cancer that is ER-positive and Her2-negative, and a 
potential target is insulin-like growth factor signaling, to which clinicians adopt IGF-1R antibody 
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or small molecule inhibitors to block this pathway (Atzori, Traina et al. 2009). In addition, 
endocrine therapy plus PI3K inhibitors dramatically improve treatment efficiency for luminal B 
breast cancer, while highly specific PI3K inhibitors are in development to reduce unexpected side 
effect (Creighton, Fu et al. 2010). Patients that are Her2-positive are likely to have poorly 
differentiated tumors with a relatively high level proliferation rate and associated with increasing 
risk of recurrence and death. Trastuzumab, which is an engineered antibody with a high affinity 
for Her2 extracellular transmembrane protein, has had a major impact in the treatment of Her2-
positive metastatic breast cancer with cytotoxic agents (Hortobagyi 2005). In terms of treating 
DCIS, there are three major options: 1) Breast-conserving surgery and radiation therapy with or 
without tamoxifen; 2) Total mastectomy with or without tamoxifen; 3) Breast-conserving surgery 
without radiation therapy, but the results are pending because of poor accuracy. 
Biomarkers for breast cancer 
Cancer biomarker refers to any molecule secreted by tumors or responses of body that are 
indicative of the presence of the cancer. Genetics, epigenetics, proteomics, metabolomics, 
glycomic as well as imaging biomarkers can be applied to cancer diagnosis, prognosis and other 
aspects. For breast cancer, although classical histopathological features play important roles in 
diagnosis, prognosis and treatments, in the era of big data, several novel biomarkers have been 
proposed and validated to improve clinical prediction and have become clinical routine tests for 
breast cancer. Genetic alternations in either BRCA1 or BRCA2 seem to account for about 20-25% 
of familial cancer incidences, which consists approximately 5-10% all breast cancer cases (Easton 
1999). Particularly the 3 major mutations are: 185delAG, 5382insC in BRCA1 and 6174delT in 
BRCA2. BRCA1 mutations carrier have a dramatically lower short-term and long-term survival 
rates and a significantly lower progression-free survival rate, while BRCA2 mutation does affect 
neither short-term nor long-term survival rate but associates with an increased risk of pancreatic 
cancer (Lee, Park et al. 2010). Estrogen receptor (ER) is the most important biomarker in breast 
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cancer and its status directs the therapy option to endocrine therapies because all the ER-positive 
tumors use steroid hormone estradiol as their primary growth stimulus. Progesterone receptor (PR) 
expression is dependent on the present of ER and there is <1% of breast cancer cases express only 
PR but not ER. Considering breast cancer early detection, serum tumor marker like 
carcinoembryonic antigen (CA) has not been demonstrated to be sensitive for early detection 
(Hayes 1996), while mammaglobin and maspin seems to be promising for that purpose (Maass, 
Nagasaki et al. 2002; O'Brien, Maguire et al. 2002). From the point of view of diagnosis, 
cytologic examinations for nipple duct fluid has used for decades and one study which applied 
protein chip method to analyze nipple fluid revealed some potential biomarkers, e.g., a 15940-Da 
protein was found with a 80% sensitivity and 100% specificity (King, Chew et al. 1983; Sauter, 
Zhu et al. 2002). Immunohistochemical staining for other glycoproteins such as B72.3, a-
lactalbumin and milk fat globule, showed their potential in identifying metastasis in breast cancer 
(Lee, DeLellis et al. 1984; Hilborne, Cheng et al. 1986). Furthermore, the functions of DNA 
ploidy and S-phase fraction in predicting prognosis have been put forward a long time ago but 
vary greatly among studies. Currently, neither the American Society of Clinical Oncologists (Bast, 
Ravdin et al. 2001) nor the College of American Pathologists (Hammond, Fitzgibbons et al. 2000) 
recommend ploidy status and S-phase fraction as standalone prognostic marker. Ki-67 staining is 
a common method to reveal cell proliferation and it is more consistent than ploidy and S-phase 
fraction measurement alone. The epidermal growth factor receptor (EGFR) are overexpressed 
widely among breast cancers and famous Her2/neu is a member of EGFR and amplified in 10-34% 
invasive breast cancer (Ross and Fletcher 1999). Both molecular techniques and morphology 
techniques are applied to measure Her2/neu status clinically.  Immunohistochemistry staining, 
fluorescent in situ hybridization, southern blot, RT-PCR, and enzyme-linked immunosorbent 
assay (ELISA) are common methods to test Her2/neu but none of these methods is perfect (Hillig, 
Thode et al. 2012). Additionally, Her2/neu is also an important marker in monitoring treatment 
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for trastuzumab (Esteva, Cheli et al. 2005). Besides EGFR, other growth factor like transforming 
growth factor a (TGF-α), TGF-β, insulin-like growth factor (IGF) - I and –II, platelet-derived 
growth factor (PDGF), fibroblast growth factor (FGF) and vascular endothelial growth factor 
(VEFG) are all associated with breast cancer prognosis to some extent (Bonneterre, Peyrat et al. 
1990; Castellani, Visscher et al. 1994; Yiangou, Gomm et al. 1997; Dumont and Arteaga 2000; 
Shao, Nguyen et al. 2000; Linderholm, Lindahl et al. 2001). 
Genomic instability and flow cytometry 
Genomic instability indicates an increased rate of genomic aberrations of a cellular lineage and it 
is believed to be necessary for carcinogenesis. Those alternations include nucleic acid sequence 
changes, chromosomal rearrangements and aneuploidy. Genomic instability was first 
characterized in colorectal cancers in two groups: microsatellite instability is due to defects in 
DNA mismatch repair, causing mutations in gene sequences at simple repeats; the other type, 
which is much more common, is called chromosome instability (CIN) (Lengauer, Kinzler et al. 
1997; Lengauer, Kinzler et al. 1998). The underlying mechanism is not well known but it likely 
results from elevated rate of chromosome missegregation during mitosis. Telomere dysfunction 
has also been presented as another mechanism for genomic instability (Artandi and DePinho 
2000). Traditionally, many breast genomic alternations were described as gains and losses, 
including DNA amplifications at 11q13, 17q12, 8p12 and 8q24 from cytogenetic analyses, FISH 
and CGH (Gray, Collins et al. 1994). The advent of array CGH improves the analysis and 
contributes to identify copy number variation, single nucleotide polymorphism at a high-
resolution genomic profile level (Loo, Grove et al. 2004; Bergamaschi, Kim et al. 2006; Staaf, 
Jonsson et al. 2011; Krepischi, Achatz et al. 2012). Aneuploidy, a type of chromosomal 
abnormality, represented by numerical changes in whole chromosomes, is usually indicated by 
abnormal DNA content. Aneuploidy consistently occurs in all cancers but is less well studied 
than structural chromosome alternations. Since genes and pathways which are deregulated by 
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aneuploidy are still unknown, it is possible that these genomic alternations have a more complex 
effect on carcinogenesis. In aneuploid chromosomes, candidate genes are more difficult to 
identify due to big genomic regions and potential gene-gene interactions (Gordon, Resio et al. 
2012). Flow cytometric measurement of nuclear DNA content renders reliable information about 
DNA ploidy and estimation of tumor cell genetic instability. DNA index, which is the ratio of 
tumor sample / standard DNA fluorescence channel measured by flow cytometer, is frequently 
applied to show DNA content difference among tumors, has become a prognostic and diagnostic 
marker in cancers (Pradhan, Abeler et al. 2012; Giaretti, Monteghirfo et al. 2013). Initially, dyes 
that binds double strand DNA must be added into single cells suspension. The scheme is that the 
stained cells have incorporated an amount of dye proportional to the amount of DNA measured in 
the flow cytometer and the emitted fluorescent signal yields an electronic pulse that is 
proportional to the total fluorescence emission from the cell. Considering the scatter provided by 
the cytometer, forward scatter is designed to measure cell size, while side scatter is used to 
indicate cellular complexity and granularity.  This combination of scattered and fluorescent light 
is picked up by the detectors, and, by analyzing fluctuations in brightness at each detector, it is 
then possible to collect various types of information about the physical and chemical structure of 
each individual particle. The fluid rate should not be too high in order to yield a good signal of 
discrimination between singlets or doublets and the final collected cell number should be more 
than 5000.  As DNA content could be not shown directly by flow data and thus reference cells for 
example human red blood cells, chicken red blood cells or some external control, should be 
included every time to help identify the positions of normal diploid DNA. 
Long non-coding RNA 
Long non-coding RNA (lncRNA) is a transcribed non-coding RNA molecule greater than 200 
nucleotides in length. LncRNA is an emerging focus in biomedical research. Studies have now 
demonstrated or implicated lncRNAs as important participants in a wide spectrum of processes in 
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the normal or abnormal development in organisms even though it was termed as “junk” or 
“transcriptional noise” several decades ago. Scientists had found some lower order animals have 
much larger genomes than that of higher animals including humans. The C-value paradox: why 
the amount of DNA in the haploid genome does not correspond with organism size or 
developmental complexity, was firstly solved by the discovery of non-protein-coding transcripts 
(Thomas 1971). In 1970s, with the advancement of biotechnique, e.g., DNA-RNA hybridization, 
it has been suggested that human would not have >20,000 genes and the rest space of human 
genome were mostly possessed by noncoding genes, which was called “junk DNA” at that time 
(Comings 1972). However, massively distributed non-coding genes also brought scientists 
another hypothesis: junk DNA may be useful, and a number of early hypothesized functions were 
also proposed, including genome integrity, gene regulation, mRNA processing, etc. (Britten and 
Davidson 1971; John and Miklos 1979; Lewin 1982). More transcripts that do not account for 
coding sequences have been found, e.g., tRNAs, rRNAs, snoRNAs in 1970s and 1980s but 
scientists could not elaborate non-coding genes until late 1990s, with the invention of whole-
genome sequencing. Now, it has been estimated that approximately 70-90% of human genome 
will be transcribed at some points during development in spite of low inter-species conservations 
and some low expression transcripts (Wang, Zhang et al. 2004; Djebali, Davis et al. 2012; Mercer, 
Gerhardt et al. 2012); conserved lncRNAs number only a few thousand (Ponjavic, Ponting et al. 
2007). It might be because lncRNAs don't require very much nucleotide sequence conservation to 
maintain their functionality, as compared with protein coding genes which are under strong 
selection restraints to maintain codons or open reading frames (Ponting, Oliver et al. 2009). 
However, one recent paper calculated and found a higher sequence conservation in lncRNA 
promoters than that in protein coding genes promoters in mice, indicating although lncRNA 
sequences might not be highly conserved, the level of their transcription is (Carninci, Kasukawa 
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et al. 2005). To classify a large magnitude of lncRNAs, one of useful manners is to sort according 
to their genomic locations, by which we can categorize them into five distinct groups:  
1) Stand-alone lncRNAs, which are located in small or large interspace of protein-coding genes 
(Cabili, Trapnell et al. 2011). 
2) Pseudogenes, which are extra genes copies that have lost their protein-coding potential. Only 
a small portion of pseudogenes are transcribed and also have acquired function during 
resurrection (Bekpen, Marques-Bonet et al. 2009). 
3) Natural antisense transcripts (NAT), which are derived from the opposite strand to sense 
DNA strand. About 70% of sense transcripts have been found with some antisense 
counterparts (He, Vogelstein et al. 2008). Sense-antisense pairs can be formed by two coding 
mRNAs, coding/non-coding RNAs or dual non-coding RNAs. 
4) Intronic non-coding RNAs, which are harbored within introns. 
5) Transcription elements associated transcripts, which are non-coding RNAs produced or 
processed within or near the sequence of promoter, enhancer or transcription start site in both 
sense and antisense direction.  
From various studies in lncRNAs in last decade, it is now obvious that lncRNAs contribute to a 
variety of developmental processes and diseases, but mostly the molecular mechanism details that 
lncRNAs employ have not been demonstrated or verified. Based on a few relatively well-studied 
examples, we can still distill the functions into several types though many lncRNAs may be 
implicated in various mechanisms. One of the major themes is about the role of lncRNAs in 
epigenetics. LncRNAs of this group can both interact with chromatin in cis, regulating genes 
nearby; or in trans, functioning towards distant genes. Chromatin-modifying elements such as 
polycomb repressive complex 2 (PRC2) recently have been found to interact with multiple 
lncRNAs recently (Khalil, Guttman et al. 2009; Tsai, Manor et al. 2010; Aguilo, Zhou et al. 2011; 
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Guil, Soler et al. 2012). HOTAIR, an lncRNA transcribed from HOXC cluster, is one of the best-
studied lncRNAs that dictates methylation of H3 on K27 and thus repress genes expression by 
interacting with PCR2 (Rinn, Kertesz et al. 2007). Not only PRC2, HOTAIR was also found to 
bind a second complex containing CoREST, REST and LSD1 in a different location to 
demethylation H3 on K4 and thereby inhibit target gene activation (Tsai, Manor et al. 2010). 
Similarly, lncRNAs KCNQ1OT1 and Air recruit chromatin-modifying complex to silence 
multiple gene in their imprinted gene domains, respectively. KCNQ1OT1 interacts with PRC2 
and G9a, both of which are histone methlytransferases, in cis to repress gene expression, while 
Air only brings G9a to its target promoter to form a repressive domain (Nagano, Mitchell et al. 
2008; Mohammad, Mondal et al. 2009).  
X chromosome inactivation (XCI) inactivates one X in female cells to equalize gene expression 
between males and females. The XCI process is largely controlled by a lncRNAs enriched cluster 
known as the X-inactivation center. Xist, a 17kb transcript, “coats” X chromosome and recruit 
silencing complex including PRC2, resulting in a chromosome-wide gene inhibition (Zhao, Sun 
et al. 2008). 
Another major function that lncRNAs have is to regulate transcription directly. LncRNA can act 
as a molecular decoy, by which lncRNA binds to specific transcription factor or other regulatory 
factors, which is necessary for target gene transcription initiation. PANDA, a p53 dependent 
lncRNA in cell cycle, works as a decoy to sequester transcription factor NF-YA away from its 
target genes to undergo cell cycle arrest (Hung, Wang et al. 2011)..  Another subtype lncRNA of 
this class works directly with Pol II. An upstream minor promoter of dihydrofolate reductase 
(DHFR) produces a lncRNA that inhibits assembling of pre-transcription elements at the major 
promoter via a mechanism of forming DNA: ncRNA complex or binding general transcription 
factor II (Martianov, Ramadass et al. 2007). 
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LncRNAs can also affect the nuclear compartment. Nuclear enriched abundant transcript 
1(NEAT1) associates with multiple paraspeckle proteins to stabilize paraspeckles (Chen and 
Carmichael 2009; Clemson, Hutchinson et al. 2009). Metastasis-associated lung adenocarcinoma 
transcript 1 (MALAT1), another very abundant lncRNA localized in nucleus, binds 
serine/arginine splicing factors. MALAT1 accounts for relocating those splicing factor to 
transcription start sites, where mRNA precursors get cleaved (Tripathi, Ellis et al. 2010). 
LncRNAs could also exert their functions in post-transcriptional steps. MALAT1, Gomafu/MIAT 
and some natural antisense transcript all play roles in mRNA splicing, as examples of post-
transcriptional regulation (Sone, Hayashi et al. 2007). In addition to process mRNA, lncRNA 
may even be able to impact mRNA stability and protein translation (Gong and Maquat 2011; 
Yoon, Abdelmohsen et al. 2012). To date, lncRNA expression analyses predominately studied by 
qPCR have reveled association between lncRNA dysregulation and diseases, most notably cancer. 
Although most lncRNAs resides in the nucleus, a proportion of lncRNAs localize within or are 
transported to cytoplasm to regulate proteins translation, localization or mRNA stability 
(Kapranov, Cheng et al. 2007). LncRNA NRON prevents the traffic of nuclear factor of activated 
T-cells (NFAT) transcription factor to nucleus from cytoplasm where it activates target genes in 
response to calcium-dependent signals (Willingham, Orth et al. 2005) . Cytoplasmic lncRNAs 
also are capable to base pair with mRNA and thereby regulate mRNA transcription and protein 
translation. For example, UCHL1 mRNA antisense, which is a lncRNA, complements to UCHL1 
AUG initiation codon and combined inverted SINEB2 domains to enhance UCHL1 protein 
synthesis in cytoplasm(Carrieri, Cimatti et al. 2012); PTENP1, a pseudogene gene of tumor 
suppressor gene PTEN, has the same microRNA binding sequences in 3’UTR as that of PTEN, 
leading to a microRNA binding competition between PTEN and PTENP1, resulting in PTEN 




Table 1. Current cancer-related lncRNAs 
lncRNA Cancer Molecular Function Reference 
HOTAIR Multiple 
cancers 
Epigenetic regulation (Gupta, Shah et al. 2010; Kogo, 
Shimamura et al. 2011; Yang, Zhou et al. 
2011; Chen, Sun et al. 2013; Zhang, Han 
et al. 2013) 
MALAT1 Multiple 
cancers 
mRNA splicing (Ji, Diederichs et al. 2003; Luo, Ren et al. 
2006; Yamada, Kano et al. 2006; 
Fellenberg, Bernd et al. 2007) 
H19 Multiple 
cancers 
Epigenetic regulation (Hibi, Nakamura et al. 1996; Berteaux, 
Lottin et al. 2005; Fellig, Ariel et al. 2005; 
Tsang, Ng et al. 2010) 
MEG3 Multiple 
cancers 
P53 activation (Zhang, Gejman et al. 2010; Braconi, 
Kogure et al. 2011; Jia, Wei et al. 2013; 
Lu, Li et al. 2013; Sun, Xia et al. 2013) 
KCNQ1OT1 Breast, colon Epigenetic regulation (Tanaka, Shiota et al. 2001; Rodriguez, 
Weng et al. 2011) 
Zfas1 Breast NA (Askarian-Amiri, Crawford et al. 2011) 
Gas5 Breast, 
pancreas 
Decoy of glucorticoid 
receptor(GR) 
(Mourtada-Maarabouni, Pickard et al. 
2009; Lu, Fang et al. 2013) 
HULU Multiple 
cancer 
Decoy of microRNA (Panzitt, Tschernatsch et al. 2007; 




Epigenetic regulation (Yu, Gius et al. 2008; Yap, Li et al. 2010) 
CCND1 NA Induced by DNA 
damage 
(Wang, Arai et al. 2008) 
BC200 Multiple 
cancers 
Protein binding (Chen, Bocker et al. 1997; Iacoangeli, Lin 
et al. 2004) 
PTENP1 Prostate Decoy of microRNA 
binding sites 
(Poliseno, Salmena et al. 2010) 
PCA3 Prostate NA (Bussemakers, van Bokhoven et al. 1999) 
PCATs Prostate NA (Prensner, Iyer et al. 2011) 
 
Different expression of lncRNAs between cancer and normal tissue indicates the potential use of 
lncRNA as a diagnostic and prognostic tool, and expanding understanding of its molecular 
mechanisms also suggest avenues to treat cancer with lncRNA molecules. PCA3, for an instance, 
has been tested in large controlled clinical settings, confirming the previous discovery of PCA3 
differential expression pattern, about 60 to 100 times higher in cancer tissue than benign prostate 
(Hessels, Klein Gunnewiek et al. 2003) . The effectiveness of PCA3 in diagnosing prostate cancer 
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is about the same as that of prostate-specific antigen (Day, Jost et al. 2011). HOTAIR, as another 
example, was found to be increased by hundreds of times in metastatic breast cancer tissues and 
also shows a robust association with patient prognosis (Gupta, Shah et al. 2010). In addition to 
breast cancer, HOTAIR was subsequently found to be associated with multiple cancers, including 
colon cancer and hepatocellular carcinoma (Kogo, Shimamura et al. 2011; Yang, Zhou et al. 
2011). Scientists also identified lncRNA MALAT1 as a prognostic factor for patients with non-
small cell lung cancer and then validated it in endometrial stromal sarcoma of uterus and liver 
cancer afterwards(Ji, Diederichs et al. 2003; Yamada, Kano et al. 2006; Lin, Maeda et al. 2007).  
Ideally biomarkers should be sampled easily, for example, from body fluids. Previous 
investigations have suggested some microRNAs are stable and detectable in blood, urine and 
sputum, while very few lncRNAs examples have been elucidated in body fluids. HULC (highly 
upregulated in liver cancer) is detectable in the blood of liver cancer and colon cancer patients by 
conventional PCR and PCA3 is also a good biomarker in urine for prostate cancer as mentioned 
above (Panzitt, Tschernatsch et al. 2007; Matouk, Abbasi et al. 2009). In addition to cancer, 
lncRNAs aberrations were also found in other diseases including Alzheimer’s diseases, psoriasis 
and heart diseases (Sonkoly, Bata-Csorgo et al. 2005; Faghihi, Modarresi et al. 2008; 
Korostowski, Sedlak et al. 2012). LncRNA Beta-secretase 1 antisense (BACEAS), which 
regulates Beta-secretase 1sense, exhibit enhanced expression in several regions of brains in 
several patients with Alzheimer’s diseases (Faghihi, Modarresi et al. 2008). Moreover, lncRNA 
psoriasis susceptibility-related RNA Gene Induced by Stress (PRINS) was named by its potential 
relationship with psoriasis by recent study (Sonkoly, Bata-Csorgo et al. 2005).  
LncRNAs might be also useful for therapeutics. Since lncRNA can recruit chromatin-modifying 
complexes to silence gene expression, it might be possible to deliver specific lncRNAs by gene 
therapy delivery systems though it could be risky. Moreover, lncRNA could also be recognized 
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by synthetic siRNAs or microRNA. For example, H19 was successfully targeted by a plasmid-
based RNAi system to advance treatment of bladder cancer and pancreatic cancer (Smaldone and 
Davies 2010; Sorin, Ohana et al. 2012). Knockdown of prostate cancer noncoding RNA 1 
(PRNCR1), which is upregulated in some prostate cancer, weakens the viability of prostate 
cancer cells and androgen receptor transactivation activity (Chung, Nakagawa et al. 2011). Not 
only being potential biomarkers or therapeutic agents, lncRNA could also be used to develop 
novel therapeutic strategies. Synthetic lncRNAs might work as decoy of transcription factor or 
microRNA, thus reduce transcription activity or microRNA expression, as Gas5 and PTENP1 do 
(Mourtada-Maarabouni, Pickard et al. 2009; Poliseno, Salmena et al. 2010). To date lncRNA has 
mostly been looked at by qPCR based and by RNA sequencing tests. However, a novel in situ 
hybridization assay allows us to investigate lncRNA expression by microscopy.  
Principle of RNAscope® chromogenic in situ hybridization assay 
RNAscope® chromogenic in situ hybridization assay is novel RNA detection system use with 
intact cells on either fresh or preserved tissues. Two independent probes (double Z probes) are 
designed to hybridize to target sequence in tandem for signal amplification, which ensure 
specificity because it has extremely low possibility that two probes will bind to non-specific 
target simultaneously. The lower part of Z probe is 18 to 25 base region that is complementary to 
target sequence and the higher part is a 14 base tail sequence that is designed to bind pre-
amplifier. Two Z probes are connected by a spacer sequence and double Z probes are designed 
specifically for each RNA target. Usually, 20 double Z probe pairs can cover 1 KB length of 
target sequence. After double Z probes hybridize to target RNA sequence, a cascade of steps is 
employed to amplify signals. Preamplifier first binds to higher region of double Z probes and then 
amplifier bind to the 20 binding sites on each pre-amplifier. Label probes containing chromogenic 
enzymes (horseradish peroxidase) are then applied to conjugate with the 20 binding site on each 
amplifier. Finally, colored RNA molecules could be visualized by bright field microscope after 
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substrate application. The general scheme is displayed in Figure 1.  Comparing with other RNA 
in situ hybridization systems, RNAscope® technology holds several advantages: 1) it is a highly 
sensitive platform because each RNA sequence only requires three double Z pairs to bind, so, 20 
double Z probe pairs should target RNA molecule robustly even it is somehow degraded. 2) it is 
highly specific because only simultaneous binding of two independent Z probes provide binding 




Figure 1. Work scheme of RNAscope® in situ hybridization assay 
 
Conclusion 
As a major cause of morbidity and mortality in women, breast cancer is one of the most critical 
diseases internationally. Tremendous effort has been made in basic research and clinical trials to 
investigate the molecular science of breast cancer and improve its diagnosis, prognosis and 
treatment. However, there are some barriers remaining for this complex disease. With advanced 
technologies, we need to pay more attention to discover useful biomarkers which can accurately 
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classify subtypes of breast cancer, especially carcinoma in situ. Though DNA ploidy change has 
been studied in FFPE samples previously, subtle intratumoral heterogeneity have not been studied, 
which might contribute to the identification of various cancer signatures in combination with 
multiparametric flow cytometry. In addition, very few investigators have used CISH to detect and 
quantify lncRNA expression in breast cancer archived samples and very few prior studies have 
looked at the connection between lncRNAs expression levels and breast histopathological 





















Alternative Tissue Sampling Method to Detect Genetic Instability of Breast 
Carcinoma with Flow Cytometry 
 
Aim: 
To test a novel approach for investigating DNA ploidy and intratumoral heterogeneity within 
solid tumors by flow cytometric analysis 
Hypothesis: 
Core punch tissue sampling allows the targeted recovery of tumor tissues from FFPE specimens 
for DNA aneuploidy and intratumoral heterogeneity analyses of breast carcinomas by flow 
cytometry. 
Material and Methods: 
Tissue acquisition 
FFPE tissue blocks of breast carcinoma were provided courtesy of Dr. Kavita Munjal 
(Department of Pathology, Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh, 
India) and normal placenta specimens were retrieved from Fletcher Allen Health Care (FAHC), 
Burlington, VT. Each breast carcinoma FFPE block was cut into 5µm section on microtome 
(Leica, Allendale, NJ) subsequently stained with hematoxylin and eosin (H&E) in the FAHC 
histology department. All H&E stained slides were reviewed and tumor regions were marked by 
Dr. Donald L. Weaver from Department of Pathology, University of Vermont. 
Tissue Sampling 
Breast cancer FFPE blocks were placed in tissue arrayer (Beecher Instrument, Silver Spring, MD) 
and 1mm diameter tumor tissue cores were punched from the blocks guided by the marked H&E 
slides. 1mm normal placental tissue cores were punched from FFPE placental tissue blocks. 
Cores were put on a piece of 50 micron nylon mesh provided by Advanced Genome Technology 
Core (AGTC) in the University of Vermont and cut by knife to remove excess paraffin wax.  
Then, tweezers were used to wrap the tissue core in nylon mesh that was then put it into 
25 
 
micromesh biopsy cassettes (Thermo electron cooperation, Pittsburgh, PA). The mesh was 
clamped down securely by the cassette lid to prevent the tissue cores from coming out of the 
nylon mesh. Post-punch FFPE block tissue sections were recut for H&E staining in order to 
confirm that core was correctly punched from tumor enriched regions. 
Single cell suspension preparation 
Several approaches were applied to deparaffinize tissue core and disaggregate cells in order to 
make single cell suspensions. The overall schemes are similar including xylene deparaffinization, 
ethanol rehydration and enzymatic treatment, but distinct treating durations and enzymes were 
tested to generate the most effective approach. According to the optimal procedures, extracted 
tissue core were placed into biopsy cassettes and then immersed into two changes of xylene 
solution (Fisher scientific, Pittsburgh, PA) for two hours, respectively. Subsequently, two changes 
of 100%, 95%, 70%, 50% ethanol (Pharmco-aaper, Brookfield, CT) were sequentially applied to 
rehydrate tissue core in cassettes for twenty minutes each. After rehydration, the cassettes were 
left in MilliQ DI water for one and a half hours to get rid of remaining ethanol.  After that, 
cassettes were opened carefully and tweezer was used to clamp mesh wrapped tissue core and 
place it into a clean 1.5ml centrifuge tube. Subtilisin Carlsberg solution was prepared by adding 
0.1%(w/v) Sigma Protease XXIV (Sigma, St.Louis, Mo) , 0.1M Tris, 0.07M NaCl to make a pH 
7.2 solution, or by using a Protease XXIV kit (Biocare medical, Concord, CA); 500µl of the 
solution was added into tubes for disaggregating cells of the tissue core at 37°C water bath 
overnight. Next morning, Orbit LS shaker (Labnet International, Edison, NJ) was applied to 
shake tubes for 20 mins after removing that tube from 37°C water bath. Then, Subtilisin 
Carlsberg solution now containing the digested cells was filtered through fresh 50 micron nylon 




For staining purpose, propidium iodide (PI), Sytox Green, SYBR Green and 4', 6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI) were used for comparison. PI solution (Sigma, St.Louis, 
Mo) was diluted from 1.0mg/ml into 1.0µg/ml by adding 10mM Tris, 10um Nacl and 1ul Nonidet 
P-40 water solution. And the prepared PI solution was mixed with Substilin Carlsberg solution in 
equivalent amount in 1.5ml dark centrifuge tube to bind both double strand and single strand 
nuclei acid. Appropriate Ribonuclease A (10µg RNase A/ 1ml PI solution -100µg RNase A /1ml 
PI solution) was added up in order to get rid of single strand RNA. The tubes were then placed in 
the dark fridge to incubate at 4 centigrade for 1.5 hours. Both SYBR Green (Life Technology, 
Foster City, CA) and Sytox Green (provided by Dr. Yvonne Janssen-Heininger’s lab) were 
required to add in 1X as the final concentration and the incubation situation was set at 4 
centigrade for 30min in dark. DAPI (Life Technology, Foster City, CA) was firstly made 5mg/ml 
stock solution in DMSO, which was diluted to 3µM in DAPI staining buffer (100 mM Tris, pH 
7.4, 150 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.1% Nonidet P-40) and the specific 
incubation situation for DAPI was 4 centigrade and 15 mins in the dark. After staining, all 
solution was transferred from 1.5ml centrifuge tube to flow cytometry tube (either provided by 
AGTC or the Department of Immunology at the University of Vermont). 
Flow Cytometry 
Two flow cytometers were utilized.  Coulter EpicsXL-MCL (Beckman Coulter, Inc, Brea, CA) is 
a flow cytometer located in the AGTC and was applied to cells suspension stained with PI, Sytox 
Green and SYBR Green. Procedures recommended by operator manual were followed. The other 
flow cytometer that was used is BD LSRII (Becton Dickinson, Franklin lakes, NJ) that locates in 
Department of Immunology in University of Vermont. Sample tubes stained with Sytox Green, 
SYBR Green and DAPI were detected by this cytometer. Procedures recommended by operator 
manual were followed. At least 5000 intact nuclei were collected for plotting a DNA histogram. 
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The diploid placental cells obtained from placental FFPE block were used as an external standard 
which was analyzed firstly to adjust the voltage of the photomultiplier in order to fix the signal of 
the diploid standard at channel position 50 and it was also measured after all the tumor samples.  
Data analysis 
FCS EXPRESS 4 FLOW CYTOMETRY – RUO [De Novo Software, Los Angeles, CA] was 
used to analyze all EpicXL- MCL LMD file and BD LSRII FCS file.  The DNA index (DI) was 
defined as the ratio of the mean fluorescence channel number of the G0/G1 in tumor sample to 
the mean fluorescence channel number of the G0/G1 in external control and the coefficient of 
variation (CV) of the G0/G1 and G2/M peaks was defined as the normalized standard deviation 
obtained by Gaussian curve fitting, both of which were analyzed by FCS EXPRESS 4 FLOW 
CYTOMETRY – RUO. Besides, other parameters like G1 phase portion, G2 phase portion, S 
phase portion and percentage of background aggregates debris (B.A.D) were also measured.  The 
best fitting curve was selected from six analysis models that already exist in software. For this 
study, a DI between 0.95-1.05 was defined as DNA diploid, and any DI < 0.95 or > 1.05, as 
aneuploidy (Corver, Ter Haar et al. 2011). To assess intratumoral DNA content heterogeneity, 
multiple cores were punched from individual FFPE tissue blocks identified by H&E review as 
containing sufficient tumor enriched regions. Within-assay coefficient of variation, which was 2% 
for DNA index analysis and 7% for %SPF analysis, was calculated with 10 cores from a placental 
FFPE block to confirm the limits for valid intratumoral heterogeneity. The assessment of 
intratumoral heterogeneity was defined by either a difference of the DNA-ploidy pattern or a 
variation of >8% (±2 x CV) in the DNA index among aneuploid patterns between tumor 
subpopulations in separate regions, or S-phase fraction difference >28% (±2 x CV) regarding 
lowest DNA index among all samples as the reference. DNA content intratumoral heterogeneity 
statistical analyses (Fisher’s exact test) were performed using GraphPad InStat (GraphPad 




The optimization of single cell suspension 
To determine which enzymes is better to disaggregate single cells from tissue core, 0.5% trypsin 
solution and 0.1% Subtilisin Carlsberg solution were applied for 1mm tissue cores that was  
punched from archived breast carcinoma FFPE tissue blocks in Experimental Pathology lab, and 
compared, following same deparaffinization and rehydration procedures.  PI was used as DNA 
binding dye in both tests. Figure 2 shows the better applicability of Subtilisin Carlsberg for cell 
releasing. 
 
Figure 2. Comparison of different digestion enzymes 
Tissue core were treated with 0.5% trypsin (A) and 0.1% Subtilisin Carlsberg (B) and subsequent flow 
cytometric analysis were compared. PI was used as binding dye for all tests and RNase A was applied to 
eliminate RNA binding. 
 
Then, we assessed different combinations of deparaffinization and enzymatic digestion to 
optimize the time for disaggregating cell. 1mm placental tissue core were used as our sample and 
PI was used for DNA binding dye.  Figure 3 shows de-wax and digestion time data. In brief, a 4h 
xylene dewaxation step plus overnight digestion rinse resulted in a histogram with a distinct and 
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narrower peak with a lower CV than a 2h xylene dewaxation plus shorter time of incubation (data 
not shown). 
 
Figure 3. Comparisons between deparaffinization time and enzymatic digestion time 
Four combinations of xylene diparaffination and subtilisin carlsberg digestion, differing in length, were 
tried and compared: 4 hours dewaxing plus overnight enzymatic digestion (A); 2 hours dewaxing plus 
overnight enzymatic digestion (B); 2 hours dewaxing plus 2 hours enzymatic digestion (C); 4 hours 
dewaxing and 2 hours enzymatic digestion (D).  Propidium iodide (PI) was used as binding dye for all tests 
and RNase A was applied to eliminate RNA binding. 
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DNA Binding affinitiy is another factor that influences flow cytometry. Four binding dyes: PI, 
SYTOX Green, SYBR Green and 4',6-diamidino-2-phenylindole (DAPI) were compared and two 
flow cytometers were used. Coulter EpicsXL-MCL was applied to only assess affinity of DNA 
binding with only PI, SYTOX Green and SYBR Green as it lacks apporporite detector for DAPI , 
as Figure 4 upper panel shows, suggesting a better applicablity of SYTOX Green and SYBR 
Green, while BD LSRII flow cytometry was subsequently used to compare SYTOX Green, 
































Figure 4. Comparisons of different DNA binding dyes 
PI (A), SYTOX Green (B), SYBR Green (C) DNA binding affinity was tested with Beckman Coulter 
EpicsXL-MCL; DAPI (D), SYBR Green (E), SYTOX Green (F) DNA binding affinity was assessed by BD 
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To verify our temporary conclusion that DAPI was the most appropriate dye, we set up another 
test to compare the results that SYBR Green produced with two flow cytometers to exclude any 
bias on machines. Figure 5 demonstrates that BD LSRII generated result is much better than that 
of Beckman Coulter EpicsXL-MCL with the same DNA binding dye, suggesting DAPI would be 
the best option for our subsequent analysis. 
 
Figure 5. Comparisons of two flow cytometers 
SYBR Green was used as DNA binding dye to compare flow cytometry results generated by each flow 
cytometers: Beckman Coulter EpicsXL-MCL (A) and BD LSRII (B) 
 
The application of novel core punch sampling method to show DNA ploidy 
Of the 31 breast carcinoma specimens (1 DCIS, 1 medullary, 1 invasive ductal 
carcinoma/invasive lobular carcinoma, 2 pure invasive lobular carcinoma, 26 pure invasive ductal 
carcinoma), 23 (74%) were shown as aneuploidy by our novel sampling method, while 8 (26%) 
were diploidy. Pre-punched and post punched H&E stain slides was made to confirm proper 
tissue selection, as Figure 6 showed. Figure 7 exhibits various aneuploidic examples. 
 
FITC-SYBR Green


















Figure 6. Identification and sampling of tumor rich regions in FFPE tissue blocks 
(A) Hematoxylin and eosin (H&E) stained slide marked for tumor (blue line) and normal cell regions 
(black line). (B) Post-punch FFPE block. (C) Pre-punch H&E stained tumor (D) Post–punch H&E to 








Figure 7. DNA content profiles from selected individual core punch samples 
(A) FFPE normal placental cells with DI=1.00. (B) Tumor adjacent normal cells DI=1.00, showing the 
correspondence of normal DNA content profiles from breast and placenta tissues. (C) DNA content 
histogram showing a hyperdiploid tumor with DI=1.72. (D) Multiploid tumor showing hyperdiploid 
(DI=1.08 [grey]) and hypodiploid (DI=0.72 [blue]) populations. (E) Hypertetraploid tumor with DI=2.67. 
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The application of our novel core punch sampling method: to detect subtle intratumoral 
heterogeneity 
Among all 31 specimens, 23 tumors had sufficient tumor for 2 or more core-punches, 3 (13.0% 
[all IDC: 1 moderate, 1 poorly differentiated]) showed diploidy only; 20 (87.0% [3 moderately, 
17 poorly differentiated]) were aneuplodic: 10 (43.5%) showed no significant variation in DI and 
10 (43.5%) showed DI intratumoral heterogeneity; 11 (47.8%) showed %SPF intratumoral 
heterogeneity, 7 (30.4%) showed both DI and %SPF heterogeneity. Figure 8 displays 2 cases with 
intratumoral DNA index heterogeneity and 1 case with intratumor S-phase fraction heterogeneity. 
 
Figure 8. Intratumoral DNA heterogeneity demonstrated by core punch tissue sampling 
Histogram group A and B generated by cores in the same tissue block showing DNA index heterogeneity 
with (A1) DI=1.71 vs. (A2) DI=1.39; (B1) DI=1.47 vs. (B2) DI=1.62. Intratumor percentage S-phase 






Patient ages ranged from 35 to 95 years (mean 52.1); tumor size from 10 to 80 mm (mean 37.0); 
tumor stage 1 (n=7), 2 (n=15), 3 (n=5), 4 (n=4); ER positive 17 (54.8%), ER negative 14 (45.2%); 
PR positive (64.5%), PR negative 11(35.5%); HER2 positive 10 (32.3%), HER2 negative 21 
(67.7%). There were no significant differences (P>0.05) of DI and/or %SPF intratumoral 
heterogeneity with reference to any of these parameters. 
Discussion: 
The main findings of this study are two-fold: firstly, that core-punching is an effective method for 
sampling cells from FFPE specimens for flow cytometric DNA content analysis, and secondly 
that DI and %SPF intratumoral heterogeneity are relatively common events in breast tumors even 
within focal tumor localized within a single surgical block. 
Previous FFPE specimen studies have assessed DNA content from intact nuclei recovered from 
≥50 µm whole tissue sections prepared by microtomy. Thick sections are required as DI index 
and the proportion of cells scored as aneuploidic increases significantly comparing sections cut to 
a thickness of 5, 10, 20, 40, or 80 mm and the thinner the section the greater the cellular debris 
generated (Kallioniemi 1988). Punching recovers 1 mm diameter cores through the depth (up to 
several millimeters) of a tissue block and as such is a highly effective approach for recovering 
intact nuclei. Besides, with the margined tumor rich regions on tissue blocks, punching targets 
much more specifically on tumor cells instead of including abundant normal adjacent cells around 
by cutting whole sections that possibly lower or remove comparative tumor cell population 
proportion in our scale (Figure 9). The potential disadvantages are the assumption that tumor 
identified at the block surface is present through the depth and the lack of ‘internal control’ 
normal diploid cells in a tumor rich region; whole sections are more likely to contain sufficient 
control reference cells; however, the very presence of these cells also impair DNA 
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content/aneuploidy assessment (Hedley, Friedlander et al. 1983). The tissue blocks available for 
this study lacked high cellularity normal adjacent tissues. FFPE normal placental tissue was used 
instead and its status as a viable diploid control confirmed by comparing multiple (10) cores to 
confirm consistent DNA content measurement. The core approach was then used to investigate 
intratumoral DI and %SPF values within a surgical block: heterogeneity was found in 43.5% and 
47.8% of breast tumors respectively. 
Several previous studies have investigated DNA content heterogeneity comparing different 
samples of gross dissected fresh tumors or serial FFPE sections or sections from alternative 
blocks (Table 2). Assay of multiple samples is recommended to detect aneuploidy; for example, 
Bergers and his colleagues (Bergers, van Diest et al. 1996) reported that at least six separate areas 
required measurement in order to fully detect heterogeneity. In the present study, tumor within an 
FFPE block was sampled at 2-3 tumor rich sites. The heterogeneity detected is within the range 
found in previous studies (Table.15). Practically, this shows that selective core punching of tumor 
regions requires less extensive tissue usage to reveal heterogeneity than a whole section approach. 
Biologically, these data show that even DNA content heterogeneity can be a highly localized 
event within a tumor. 
With the advent of improved dyes and instrumentation, there has been a resurgence of interest in 
the use of flow cytometry for the analysis of FFPE specimens. Multiparametric techniques enable 
combined DNA content and protein biomarker assay through the combined use of labeled 
antibodies (Corver and ter Haar 2011; Dayal, Sales et al. 2013). Multiparametric approaches in 
conjunction with core punching will likely provide more refined data than is possible from a 
whole section approach. Studies investigating the relationship of DNA content heterogeneity to 






Figure 9. Comparison of core punching and whole section tissue sampling method 
One FFPE tissue block was sampled by cutting whole section (A) and alternative punching method (B), 
stained by DAPI and compared by BD LSRII flow cytometer. Normal adjacent cells were drawn in black 
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(Prey, Meyer et al. 1985) 
 
8 5–11 67 - 
     
 
(Kallioniemi 1988) 104 3–10 13 36 
     
 
(Meyer and Wittliff 1991) 61 2–31 26 - 
     
 
(Bonsing, Beerman et al. 
1993) 18 1–11 67 
- 
     
 
(Schvimer, Lash et al. 1995) 28 3 43 - 
     
 
(Danesi, Spano et al. 1997) 102 Not given 28 - 
     
 
(Arnerlov, Emdin et al. 
2001) 48 4–5 44 
71 
     
 
The present study 23 2–3 44 47 
 
Conclusion: 
The first study demonstrates that a core-punching method is effective to release cells from FFPE 
tissue specimens for flow cytometric DNA content analysis, which is a standard techniques to 
detect abnormal cell in terms of either chromosome abnormalities or disordered cell cycle. The 
composite analysis of the results from this investigation well illustrates that this alternative tissue 
sampling method is able to release intact single cell for flow cytometry from one 1mm diameter 
tissue core punched in depth from preserved tissue blocks.  We were able to perform flow 
cytometric analysis with this new method to reveal both normal and abnormal DNA ploidy. 
Comparing with typical whole tissue sections cell releasing strategy, this new technique can 
provide more accurate tumor cell ploidy status without taking much adjacent normal cells into 
account. More importantly, by using current method, we identified intratumoral heterogeneity 
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either in DNA content or S phase fraction, from different cores that were retrieved from single 
surgical blocks, indicating even within a single piece of solid tumor, tumor cell populations may 
come from distinct clones and undergo complicated mutations along tumor develops. Our 
findings can provide some insights not only for breast cancer biomarker discovery that looks for 
precise DNA abnormality pattern, but also for breast cancer therapeutics regarding intratumoral 
heterogeneity. Although internal control is lacking, external control normal placental cells seems 














Long non-coding RNA Chromogenic in situ Hybridization Signal Patterns Correlate 
with Breast Tumor Pathology 
 
Aim 
To apply a novel RNA in situ hybridization detection technology for the investigation of lncRNA 
expression in FFPE specimens and to assess the relationship between six lncRNAs and common 
breast tumor markers using tissue microarrays. 
Hypothesis 
RNAscope® CISH can be used to substantiate lncRNAs identified as potential markers of breast 
cancer by qPCR or RNA sequencing studies.  
Material and Methods 
Tissue microarray (TMA) preparation 
All FFPE tissue blocks of breast carcinoma and DCIS were retrieved from FAHC archives. FFPE 
blocks were recovered for 52 patients identified by electronic record search by pathology 
residents Drs. Daniel Olsen and James deKay as having concurrent DCIS and invasive breast 
cancer (IC). Each FFPE block was sectioned, stained by H&E and subsequently reviewed by Dr. 
Donald L. Weaver.  Regions of DCIS, IC and normal adjacent epithelia (NA) were marked on the 
slides and used to guide core punching (one core punch per NA, DCIS or IC region per patient) 
for the construction of the TMAs from the companion FFPE surgical blocks. A tissue arrayer 
(Beecher instrument, Silver Spring, MD) was used to prepare tissue microarray FFPE blocks. A 
one millimeter diameter receptor needle was used to extract cores from a FFPE block and relocate 
it into a recipient paraffin block. Tissue cores from same individuals were made in the same 
horizontal line, separated by tissue types.  Five tissue microarray FFPE blocks were made by this 
technique and each block contained about ten invasive cancer spots, ten DCIS spots and ten NA 
tissue spots with one separated head and neck tumor tissue spot as location control (line 1, 3, 5, 7, 
9), as shown in Figure 10. Five TMA blocks were placed in Thelco® laboratory oven (Jouan, Inc., 
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Winchester, VA) to incubate overnight at 60℃. One section of five micrometer tissue section of 
each TMA block was cut, stained and reviewed by pathologists in FAHC. 
 
Figure 10. Tissue microarray design 
A) diagram of tissue microarray block; B) actual TMA 
 
LncRNA in situ hybridization process 
Five micrometer tissue slides were made and baked in Thelco® laboratory oven (Jouan, Inc., 
Winchester, VA) overnight at 60℃. Generally, RNAscope® FFPE in situ hybridization assay 
platform (Advanced Cell Diagnostic, Hayward, CA) was applied in our study with minor 
modification on pre-treatment steps. The optimal procedures were listed in a flow diagram in  
figure 11. Positive control POLR2A (P/N 310451, Advanced Cell Diagnostic, Hayward, CA) and 
negative control DapB (P/N 310043, Advanced Cell Diagnostic, Hayward, CA) were tested for 
each lncRNA probe. To ensure the RNA targeting specificity of ACD lncRNA probes, we applied 




Aldrich, St. Louis, MO) treatment step right after pretreat 3 and compare the results to that of 
regular procedures.  RNase A was diluted to 100µg/ml in phosphate buffered saline (PBS) 
(Sigma-Aldrich, St. Louis, MO) and then 100µl RNase A solution was applied to cover and 
incubate tissue section for thirty minutes at room temperature, followed by Milliq water washing 
for five minutes for three times. Similarly, 50µg/ml DNase I work solution was mixed by DNase 
I, 10x DNAse I reaction buffer (P/N y02340, Invitrogen, Carlsbad, CA) and Buffer AE (Qiagen, 
Valencia, CA) and 100µl DNase I work solution was added to cover and incubate tissue section 
for fifteen minutes at room temperature. Three times of Milliq water washing for five minutes, 































 Two changes of Xylene 
 Two changes of 100% ethanol 
 Air dry 
 Circle the tissue  
Pretreatment steps 
 Pretreat 1  
 Pretreat 2 (with Decloaking chamber, 100℃, 
15min) 
 Pretreat 3 (with HybEZ oven, 40℃, 30min) 
Hybridization    Probes hybridization  
(with HybEZ oven, 40℃, 2 hours ) 
                       Amplification & Detection 
 Amplification 1 (with HybEZ oven, 40℃, 30min) 
 Amplification 2  
 Amplification 3 (with HybEZ oven, 40℃, 30min) 
 Amplification 4  
 Amplification 5 (with HybEZ oven, 40℃, 30min) 
 Amplification 6 
 Detection with DAB-A and B mixture  
 
Counterstain & Mount 
 Gil’s hematoxylin solution  
 One change of 70% ethanol and  
two changes of 100% ethanol 
 One change of xylene  




Three antibodies (EZH2 (D2C9) XP(R) Rabbit mAB:  Cell Signaling, Danvers, MA; p53 (Y5): 
Thermo Fisher Scientific, Waltham, MA; CDKN1C/p57 antibody [EP2515Y], N-term: GeneTex, 
Irvine, CA) were tested on five tissue microarray slides. Several tests were done to optimize 
antigen retrieval time, antibody concentration and antibody hybridization duration, which usually 
varies depends on antigens. The overall protocol is similar to standard chromogenic 
immunohistochemistry with HRP protocol that was established by Experimental Pathology 
laboratory of the University of Vermont, including deparaffinization, antigen retrieval, non-
specific antigen block, primary antibody hybridization, secondary antibody incubation, DAB 



























Figure 12. Work flow of immunohistochemistry 
 
 
 Counterstain with Hematoxylin solution  
 Rinse with TBS 
 Rinse with tap water  
 Mount with Cytoseal 
               Counterstain & Mount 
Deparaffinized steps 
 Three changes of Xylene 
 100%, 95%, 70%, 50% ethanol, Millq water 
 Air dry 
 Circle the tissue  
Target retrieval  Heat tissue slides in Decloaking chamber. 
Incubation time depends on each target protein  
Peroxidase/Protein block  
 H2O2/PBS peroxidase block  
 Dako protein block 
                               Detection 
Antibody hybridization 
 1st antibody 
 Incubation duration/antibody concentration 
varies 
 Dual polymer for thirty minutes 
 Detection with chromogen DAB+ solution  
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RNA in situ hybridization/ Immunohistochemistry evaluation criteria 
Both RNA and protein markers expression level were scored. Two score systems were used: 
visual scoring system and RNAscope SpotStudio
TM 
software scoring system. Visual scoring 
system has been well established for years to assess immunohistochemistry and in situ 
hybridization stain, so all our markers were scored by eye. RNAscope SpotStudio
TM 
software is a 
automated, semi-quantitative scoring software that specializes in scoring RNAscope based 
images. Since it was designed to only recognize and analyze punctate dot, it was only used to 
provide score for lncRNA HOTAIR and KCNQ1OT1. 
 Visual scoring system 
RNA markers 
Bright field microscope was used to evaluate stain by experienced pathologist, Dr. Donald 
Weaver. According to various staining patterns, different scoring criteria were applied and an 
overall stain grade (SG) was generated by adding up all subgrades. Besides overall stain grade, 
we also categorized lncRNA and protein markers expressions into 1) four scale patterns, 
including negative, weak positive, moderate positive and strong positive and 2) two-tiered 
dichotomous score, which represents low and high expressional group. For HOTAIR, three 
variables: stain intensity, copy number per cell and stain proportion, were used. Stain intensity 
was divided into two levels, which are low to medium and medium to high, and was assigned 
score of 1, 2, respectively. Copy number per cell was stratified into low (1) and high groups (2) 
based on visual experience and three copies per cell was the cut-off value. Upon stain proportion, 
a generic rule was used for all RNAs and proteins except for lncRNA H19 because of its special 
staining format. We gave a case score of 0 once it was not stained or it only had positive stained 
cells less than 10%; score of 1 was given if one case had about 10-50% positive cells; 2 was 
assigned if it had positive cells ranging from 50-75% and 3 was for cases which had more than 75% 
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cells positive. So, by adding up three subgrades, the overall stain grade for HOTAIR ranged from 
2 to 7. Similar to HOTAIR, we applied intensity, copy number per cell and stain proportion to 
assess KCNQ1OT1. The only difference was the cut off value of copy number per cell in 
KCNQ1OT1 was 2, which meant any cases with majority cell stained more than 2 copies was 
called high, and vice versa.  Therefore, the overall stain grade of KCNQ1OT1 was ranged from 0 
to 7.  We assessed H19 by copy intensity and proportion. Copy density was given from 0 to 3, 
which represents negative, low, medium and high, and proportion was given from 0 to 3, showing 
four different portion levels: negative, dots, patchy and diffuse. Thus, the overall score of H19 
was from 0 to 6. MEG3 was assessed by stain intensity, which we assigned 1, 2, 3 to low, 
moderate and high intensity, respectively, and stain proportion, which was the same as that of 
HOTAIR and KCNQ1OT1. In general, stain grade of MEG3 was from 0 to 6.  Regarding four-
tiered scoring pattern for HOTAIR and KCNQ1OT1, any case with at least two of three scoring 
variables in lowest end were weak positive, any cases with high copy number, strong stain, and 
more than 50% of cells stained were in strong positive. The rest cases were all in moderate 
positive category.  For H19 and MEG3, any subjects with both two scoring variables scored no 
greater than 1 were weak positive, subjects scored more than 5 were strong positive, indicating 
one of the two variables must be highest and the other should be at least second highest, while the 
others were all moderate positive. However, KCNQ1OT1, H19 and MEG3 had another group of 
negative case. Additionally, we dichotomized all markers into low and high group to further 
reduce categories. To HOTAIR, we gave 0 to low HOTAIR group, in which cases with score of 
2-3, and 1 to cases with score of 4-7, suggesting any case with at least two of three scoring 
variables in lowest end were low and the others were high. To KCNQ1OT1, the rationale of two-
tiered system was both negative cases and any positive subject had all three scoring variables in 
lower end were given a 0, while others were 1. To H19, cases which either were negative or had 
low copy density with signal as dot, was in low and the rest were in high group. To MEG3, the 
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cut off value is 1, indicating a case that either were negative or had weak stain in less than 10% 
cells was 0. 
Table 3. Visual scoring system for lncRNA 
a) HOTAIR 
 stain intensity copy number 
per cell 
stain proportion 
HOTAIR low – medium medium –high 0-3 >3 <10% 10%-50% 50%-75% >75% 
 1 2 1 2 0 1 2 3 
 
b) H19 
 copy intensity stain proportion 
H19 low medium high dot patchy diffuse 
 1 2 3 1 2 3 
 
c) KCNQ1OT1 
 stain intensity copy number 
per cell 
stain proportion 
KCNQ1OT1 low – medium medium -high 0-2 >2 <10% 10%-50% 50%-75% >75% 
 1 2 1 2 0 1 2 3 
 
d) MEG3 
 stain intensity stain proportion 
MEG3 low Medium High <10% 10-50% 50-75% >75% 









Table 4. Four tiered pattern and dichotomous scoring system of lncRNA 
lncRNA Four tiered scoring system Dichotomous scoring system 
 Neg W M S Low group (score=0) High group (score=1) 
HOTAIR SG=0 SG=2-3 SG=4-5 SG=6-7 SG=2-3 SG=4-7 
H19 SG=0 SG=1-2 SG=3-4 SG=5-6 SG=0-2 SG=3-6 
KCNQ1OT1 SG=0 SG=2-3 SG=4-5 SG=6-7 SG=0-3 SG=4-7 
MEG3 SG=0 SG=1-2 SG=3-4 SG=5-6 SG=0-1 SG=2-6 
Neg= negative; W= weak positive; M= moderate positive; S= strong positive; SG=stain grade 
 
 Protein markers 
We applied similar scoring system to assess protein makers. EZH2 was assessed based on 
intensity and proportion as MEG3. Intensity was categorized into low, moderate and high with a 
score of 1, 2 and 3, respectively; Proportion was set as other lncRNAs. The overall stain grade of 
EZH2 ranged from 0 to 6 and pattern was segregated into negative (SG=0), weak positive (1-2), 
moderate positive (3-4), strong positive (5-6). For further simplification, stain grade of 1 was 
used as cut off value in EZH2 and rationale is same as MEG3. Other protein markers belong to 
clinical markers, including ER, PR, Her2, Ki67 and p53, so we scored them from a clinical 
perspective and dichotomized them into positive and negative. For ER, any case with more than 
10% cells expressed ER was called ER positive, and so does PR; For Her2, score was given to 
each case from 0 to 3 based on Her2 expression level. Any case with a score of 0 or 1 was 
considered as Her2 negative, while cases with a score of 3 were called Her2 positive. 
Confirmation of Her2 status by dual color in situ hybridization was undergone once we found 
Her2 score of 2 by immunohistochemistry. For Ki67, 15% was the cutoff point, suggesting Ki67 
positive was given to those cases with more than 15% cells expressed Ki67 protein. Ki67 protein 
was scored as 1 to 4 based on percentage of cells that were stained: <5%=1; 5-10%=2; 10-
15%=3, >15%=4.  P53 status was simply defined by whether it was stained or not. 
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Table 5. Visual scoring system for EZH2 
 stain intensity stain proportion 
EZH2 low Medium High <10% 10-50% 50-75% >75% 
 1 2 3 0 1 2 3 
 
 Other clinicopathological factors 
Other clinical information including DCIS nuclear grade, Nottingham grade, invasive tumor size, 
invasive lymph nodes and lymphovascular invasion (LVI) status were recorded in original 
diagnosis. In order to simplify variables that are continuous or have multiple groups, we stratified 
them into fewer groups. We dichotomized DCIS nuclear grade to 1 that represents cases with an 
original DCIS grade of 3, and 0 that represents any cases with a score less than 3, instead of 
having original five grades (1, 1-2, 2, 2-3, 3). Nottingham grade was initially scored from 3 to 9, 
while we applied three-tiered histological grade on Nottingham scores based on the following 
way: grade 1 tumors have a total score of 3-5; grade 2 tumors have a score of 6-7; grade 3 tumors 
have a score of 8-9.  In terms of invasive tumor size, we trichotomized in the following way: 1 
represents in a tumor less than 2cm, 2 represents in a tumor between 2cm-5cm, 3 stands for all 
cases with a tumor greater than 5cm. Subsequently, we dichotomized tumor size with a cutoff 
value of 2: any invasive lesion smaller than 2cm was assigned as 0, while any lesion bigger than 
2cm was assigned as 1. Invasive lymph node was also dichotomized based on its status: any case 





In order to apply RNAscope software to provide semi-quantitative results for individual case, all 
TMA slides were firstly scanned by Ventana® iScan Coreo system ( Ventana Medical System, 
Inc. Tucson, AZ) with high definition (HD) resolution. Scanned images of HOTAIR and 
52 
 
KCNQ1OT1 were then imported to RNAscope SpotStudio
TM 
software as a JP2000 file for further 
analysis. The other lncRNAs were ineligible for this assessment for reasons of high (MALT1) or 
negligible (Zfas1) expression or stromal expression (H19 and MEG3).  In terms of settings, for 
both lncRNAs, we kept default settings for image resolution that was 0.25, nucleus nucleus 
diameter that was 7.5µm and spot diameter which was 1.2µm since they all fit our cases well. 
Parameters of hematoxylin stain and spot stain were adjusted to better delineate cell regions and 
recognize brown spots. For HOTAIR, spot diameter of 1.2µm was selected after previews and 
kept for all cases to guarantee consistency for analysis.  However, we optimized hematoxylin 
stain parameter for each sample due to different background hematoxylin stain. We applied lower 
hematoxylin stain level to those cases which had lighter nucleus stain and vice versa.  For 
KCNQ1OT1, 1.2µm spot diameter was also selected to all our samples and we repeated 
optimizing hematoxylin stain parameter case by case. The range of hematoxylin stain value was 
from 0.05 to 0.15. Regions of interest, which was primarily regions that would be analyzed, were 
selected manually with the settings we optimized. An average of three to four regions of epithelia 
cells in each case, were delineated manually for software calculations. We also revised on regions 
of interest we selected by manually deleted those cells which were fake epithelia cells or have 
fake spots in that area once after batch run to avoid bias.  Once we satisfied, we exported the 
results part and thus we were able to see what score of estimated spots per cell the software 
calculated. 
Data analysis 
All statistical tests were performed with SYSTAT version 11. The comparisons of lncRNAs 
expression level (lncRNA score, pattern RNAscope® software results) between different tissue 
types were analyzed by non-parametric Friedman two-way analysis of variance (ANOVA). It was 
firstly applied to test lncRNAs expression difference in cases containing all three tissue types. On 
the ground of P value < 0.05, subsequent paired comparisons between each two tissue types were 
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tested with the same method. The correlations between lncRNA expression and 
clinicopathological factors in both DCIS and invasive cancer were analyzed by Pearson 
correlation test and non-parametric tests, Mann-Whitney U test for two groups and Kruskal-
Wallis  one-way analysis of variance (ANOVA) test for groups >3. Unadjusted pearson 
correlation coefficient was tested on the null hypothesis that there is no correlation between 
variables in order to highlight potential associations (p< 0.05) and subsequent Kruskal-Wallis test 
or Mann-Whitney test were used to further analyze associations. Since Kruskal- Wallis evaluates 
only evaluate differences in mean ranks to assess the null hypothesis that the medians are equal 
across the group, Pearson Chi-square test and Fisher’s exact test were used to compare 
proportional difference across groups, most for dichotomized variables. Variables with P value < 
0.05 in univariate analysis were also used in the subsequent multivariate logistic regression test. 
Spearman rank correlation tests were used to assess whether RNAscope® SpotStudio
TM 
software 
can produce consistent lncRNA score as eye scoring system. 
Results 
Sample size and clinical information 
Tissue microarray contains total of 36 NA breast tissue, 34 DCIS tissue and 43 invasive breast 
tissue collected from 46 patients. 2 of 46 patients were diagnosed as lobular carcinoma in situ 
(LCIS), which were excluded in our study. Patient ages ranged from 30 to 86 years (mean 58.4); 
tumor size from 0.04cm to 13.5cm (mean 1.8cm); DCIS nuclear grade 1(n=1), 1-2(n=4), 2(n=26), 
2-3(n=2), 3(n=11), invasive Nottingham histologic score from 4 to 9 (mean6.2).  Invasive 
histological tumor grade was determined by Nottingham histologic total score based on criteria 
mentioned previously: grade 1 (n=17); grade 2 (n=12) and grade 3 (n=13). Thus, our sample 
contains invasive tumor grade 1(17), 2(n=15), 3(n=12). Positive lymph node was detected in 
13/36(36.1%) and positive lymphovascular invasion (LVI) was found in 15/44(34.1%). In DCIS, 
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ER, PR and Her2 statuses were also evaluated in our study by IHC, while their statues in invasive 
cancer were recorded when patients received diagnosis. In DCIS, we had ER positive 
26/30(86.7%), PR positive 24/30 (80%), Her2 positive 3/16 (18.8%), hormone receptor positive 
26/30(86.7%), triple negative 1/16 (6.3%); In invasive cancer, we had ER positive 40/44(90.9%), 
PR positive 36/44(81.8%), Her2 positive 5/43(11.6%), hormone receptor positive 40/44(90.9%), 
triple negative 3/43(7.0%). Ki67 and p53 were stained by immunohistochemistry and 
dichotomized. Ki67 positive were 6/18(33.3%) and 13/35(37.1%) in DCIS and invasive cancer, 
respectively, while p53 positive were 2/20 (10%) in DCIS and 2/33(6.1%) in invasive cancer. A 


























DCIS nuclear grade  
1 1  (2.2) 
1-2 4  (9.1) 
2 26 (59.1) 
2-3 2 (4.5) 
3 11 (25) 
  
Invasive histologic grade  
1 17 (38.7) 
2 15 (34.1) 
3 12 (27.2) 
  
Lymph node status  
Positive 13 (29.5) 
Negative 23 (52.3) 
NA 8  (18.2) 
  




lymphovascular invasion status  
Positive 15 (34.1) 
Negative 29 (65.9) 
  
Molecular markers (DCIS)  
ER positive 26 (86.7) 
PR positive 24 (80) 







) 1  (6.3) 
Ki67 positive 6  (33.3) 
P53 positive 2  (10) 
  
Molecular markers (invasive cancer)  
ER positive 40 (90.9) 
PR positive 36 (81.8) 







) 3  (7) 
Ki67 positive 13 (37.1) 




Demonstration of tissue cores on TMA 
When construct TMA, normal adjacent breast, DCIS and IC tissue regions were marked on 
original H&E slides to guide core punch. To reconfirm tissue specificity on TMA, 5 microarray 
blocks were cut to make 5µm slides, stained with H&E, and then reviewed by pathologists (DL). 
Within NA tissue cores on TMA, several tissue cores only containing collagen and (or) adipocyte 
were excluded in HOTAIR and KCNQ1OT1 analysis but not in H19 and MEG3 because both 
H19 and MEG3 was stained mostly in stromal interspace while the rest two lncRNAs were all 
found in epithelia cells.  And quite a few tissue cores which were supposed to be pure DCIS or IC 
ended up with a mixture of DCIS and IC, which were graded and recorded separately. Tissue core 
H&E stains were displayed in Figure 13. 
 
 
Figure 13. H&E stain of tissue cores  
Image represents H&E stain of different tissue cores on TMA, (A)normal adjacet tissue; (B)DCIS tissue; 
(C) invasive cancer tissue; (D) mixture of DCIS and invasive cancer tissue(Left: invasive; Right: DCIS). 
All images were taken with 10X objective. [Scale bar: 20 µm] 
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Detection of lncRNA by RNAscope® chromogenic in situ hybridization assay (CISH) 
To ensure the lncRNA targeting specificity of RNAscope® assay platform, RNase A and DNase I 
digestion steps were performed to all lncRNA probes and compared with standard staining 
procedures. We confirmed that RNAscope® in situ hybridization assay was able to detect all 
lncRNAs properly on FFPE tissue slides with standard staining procedures or even plus an 
addition of DNase I treatment, however, lncRNA cannot be stained after RNase A treatment step 

















Figure 14. RNAscope® in situ hybridization assay specifically detect RNA molecules 
Images (A-C) shows the detection of H19 in invasive caner tissue,  by standard CISH(A) by standard  CISH plus a step of DNase I digestion (B by 
standard CISH plus RNase A treatment (C). Images (D-F) shows the detection of KCNQ1OT1 in invasive cancer tissue, by standard CISH (D); by 
standard RNAscope® CISH plus DNase I digestion (E) by standard CISH plus RNase A treatment (F). All images were taken using a 10X objective. 
[Scale bar: 20 µm]
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Long non-coding RNA staining results 
 HOTAIR 
HOTAIR staining was widely present as single of multiple dots in epithelia cell nuclei in all three 
tissue types. Within TMAs probed with HOTAIR, 26 NA tissue regions, 25 DCIS regions and 32 
invasive cancer tissue regions were scored by eye and RNAscope® SpotStudio
TM 
software. 
HOTAIR expression level between different tissue types were compared within same individuals 
for patients who had two or three tissue spots.  For HOTAIR, 11 patients had all three tissue types, 
15 patients kept NA breast tissue and DCIS, 20 patients kept NA and invasive breast cancer 
tissues, and 17 patients had both DCIS and invasive cancer tissues. In NA breast tissue, HOTAIR 
was scored from two to five: 2(n=2), 3(n=21), 4(n=1), 5(n=2) with a mean of 3.42 by eye and in 
terms of pattern distribution of HOTAIR in NA breast tissue, 23 cases were weak positive and 
only 3 cases were moderate positive. By RNAscope® SpotStudio
TM 
software, HOTAIR scores 
varied from 0.07 to 1.25 with a mean of 0.54 in NA breast tissue.  In DCIS regions, HOTAIR was 
given a score by eye from 3 to 7: 3(n=4), 4(n=5), 5(n=7), 6(n=4), 7(n=5) with a mean of 5.04. 
Four of them were weak positive, twelve were moderate positive and the rest nine were strong 
positive. From the perspective of software, 0.1 was given as the minimum while 13.78 was given 
as the maximum and the mean value was 2.17.  In invasive tissues, they had HOTAIR scores 
from three to seven: 3(n=7), 4(n=3), 5(n=5), 6(n=5), 7(n=12) and the mean is 5.38. Here, we had 
17 cases in strong positive, 8 cases in pattern in moderate positive and 7 cases in weak postive. 
Summary of HOTAIR stain is listed in Table 7.  However, the score assigned by software ranged 
more broadly, from 0.25 to 17.1 with a mean of 2.34. Figure 15 shows different HOTAIR 
expression levels in terms of eye based scoring criteria and their corresponding RNAscope 
SpotStudio






Table 7. Summary of HOTAIR stain 
Tissue n mean stain grade Four tiered pattern Dichotomous system 
   Neg W M S Low High 
NA 26 3.42 0 23 3 0 23 3 
DCIS 25 5.04 0 4 12 9 4 21 
IC 32 5.38 0 7 8 17 7 25 
Neg= negative; W=weak positive; M=moderate positive; S=strong positive 
A  
 
In this DCIS spot, HOTAIR signal was considered moderate to high intensity, with more than three copies 
per cell in more than 75% epithelia cells. Images were taken in 10X objective lens (left) [scale bar: 20 µm] 
and 20X lens (right) [scale bar: 10 µm] for same region. 
 
This set of images show results of case shown above, analyzed by RNAscope® SpotStudio
TM 
software 
package. Green lined cells represent cells which were estimated by software to have more than three copies 
of RNA per cell, while blue circled cells displays cells which have less than three copies per cell. However, 
black circled cells were unwanted cells which have been eliminated manually. Yellow dot represents single 
copy of HOTAIR, and blue shows HOTAIR clusters. In this case, 3526 epithelia cells were selected to have 
an estimated 8.32 HOTAIR copies per cell. Images were taken in 10X objective lens (left) [scale bar: 20 
µm] and 20X lens (right) [scale bar: 10 µm] for same region. 
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In this normal ajacent tissue spot, HOTAIR signal was recorded low to moderate intensity, with less than 
three copies per cell in about 10-50% epithelia cells. Both left images were taken with 10X objective [scale 
bar: 20 µm] and right images were same regions as left, taken by 20X microscope lens[scale bar: 10 µm] 
 
 
In this case, RNAscope® SpotStudio
TM 
 software was used to analyzed 951 epithelia cells. The overall 
estimated HOTAIR copies per cell was 0.82. Images were taken in 10X objective lens (left) [scale bar: 20 
µm] and 20X lens (right) [scale bar: 10 µm] for same region 
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H19 was stained mostly in the stromal component around breast ducts with some possibilities of 
epithelia cell stain as concentrated dots. Within TMAs probe with H19, 40 adjacent tissue spots 
including normal adjacent  epithelia cells and other normal spaces, 25 DCIS tissue spots and 35 
invasive cancer tissue spots were scored by eye. To compare H19 expression between different 
tissue types within same individuals, patients who had no less than two different tissue types were 
sorted out. For H19, 19 patients kept all three tissue spots, 23 patients had both NA and DCIS 
tissue spots, 33 patients had both NA and invasive tissue spots and 20 individuals owned DCIS 
and invasive cancer regions. In NA tissue regions, H19 was scored from 0 to 3: 0(n=22), 1(n=1), 
2(n=14), 3(n=3) with a median of 0.95, and the 22 of them was recorded as negative and 15 cases 
were weak positive and 3 cases were in moderate positive category. In DCIS spots, fewer cases 
(n=9) were scored as 0. More cases were assigned to a higher score: 2(n=8), 3(n=3), 4(n=3), 
5(n=2). The mean score of H19 in DCIS was 1.88. In terms of pattern distribution, 8 cases were 
negative; 9 cases were weak positive; 6 cases were pattern moderate positive and last 2 cases fit 
in strong positive group.  In invasive cancer spots, H19 expressed broader: 0(n=4), 2(n=1), 
3(n=4), 4(n=10), 5(n=7), 6(n=9) and the mean value was 4.08. Here, we had 16 cases in strong 
positive, 14 cases in moderate positive, 1 case in weak positive and 4 were negative. We 
summarized H19 stain in Table 8. Figure 16 shows different H19 expression levels in terms of 
different scoring criteria. 
Table 8. Summary of H19 stain 
Tissue n mean stain grade Three tiered system Two tiered system 
   Neg W M S Low High 
NA 40 0.95 22 15 3 0 37 3 
DCIS 25 1.88 9 8 6 2 17 8 
IC 35 4.08 4 1 14 16 5 30 




This image represents H19 negative in NA tissue [scale bar: 20 µm] 
 
Image shows H19 staining mainly in dots of low intensity in one NA tissue. Images were taken in 10X 
objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same regions [scale bar: 10 µm] 
 
H19 singal was detected in patch pattern with a moderate stain intensity in this DCIS spot. Images were 
taken in 10X objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same case [scale bar: 10 µm] 
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In this invasive cancer spot, H19 signal was diffusely found in strong intensity. Images were taken in 10X 
objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same region [scale bar: 10 µm] 
Figure 16. Expression illustrations of H19 by CISH 
 
 KCNQ1OT1 
Similar to staining pattern of HOTAIR, KCNQ1OT1 was mostly found in cancer epithelia cell 
nuclear as punctate dots in all kinds of tissue. Within TMAs probed with KCNQ1OT1, 30 NA 
cell spots, 25 DCIS spots and 32 invasive cancer spots were scored by both eye and RNAscope® 
SpotStudio
TM 
software. 10 individuals who kept all three types of tissue, 17 individuals who had 
both NA and DICS tissues, 21 patients who had both NA and invasive cancer tissues and 16 
patients who had DCIS and invasive cancer tissues were sorted out for further tests. Regarding to 
KCNQ1OT1 scores and pattern, all tissue types were assigned a broad range of score. For NA 
spots, scores were from 0 to 6: 0(n=5), 2(n=7), 3(n=13), 4(n=1), 5(n=3), 6(n=1) with a mean of 
2.6. To fit in our four tiered score system, 5 were negative, 20 cases were in weak positive, 4 
cases were moderate positive and 1 strong positive. By software, KCNQ1OT1 scores varied from 
0 to 1.73 with a mean of 0.45. In DCIS, we had KCNQ1OT1 score from 0 to 7 (mean=3.76): 
0(n=1), 2(n=3), 3(n=8), 4(n=5), 5(n=5), 6(n=2), 7(n=1). In terms of pattern in DCIS, weak 
positive (n=11) and moderate positive (n=10) had more number than negative (n=1) and strong 
positive (n=3). However, score given by software was narrower, from 0 to 3.46 with a mean of 
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0.86. In invasive cancer spots, visual score range was from 2 to 7 (mean=4.4): 2(n=4), 3(n=7), 
4(n=5), 5(n=8), 6(n=4), 7(n=4). 11 of them were weak positive, 12 were in moderate positive and 
9 were in strong positive group. List of KCNQ1OT1 summary is shown below in Table 9. 
RNAscope® SpotStudio
TM 
assigned lower scores than eye (mean=0.97): the minimum was 0.06 
and the maximum was 4.95. Figure 17 shows different KCNQ1OT1 expression levels in terms of 
eye based scoring criteria and their corresponding RNAscope® SpotStudio
TM   
results 
 
Table 9. Summary of KCNQ1OT1 stain 
Tissue n mean stain grade Four tiered system Two tiered system 
   Neg W M S Low High 
NA 30 2.60 5 20 4 1 25 5 
DCIS 25 3.76 1 11 10 3 12 13 
IC 32 4.40 0 11 12 9 11 21 













KCNQ1OT1 negative in invasive breast tissue [scale bar: 20 µm] 
 
In this NA tissue, KCNQ1OT1 was stained as punctate dots in low to moderate intensity, with a one to two 
copies per cell in less than 10% epithelia cells. Images were taken in 10X objective lens (left) [scale bar: 20 
µm] and 20X lens (right) for same region [scale bar: 10 µm] 
 
The results generated by RNAscope® SpotStudio
TM 
software package for above case were shown here   . 
Green lined cells represent cells which were estimated by software to have more than two copies of 
KCNQ1OT1 RNA per cell, while blue circled cells displays cells which have less than two copies per cell. 
However, black circled cells were unwanted cells which have been eliminated manually. Yellow dot 
represents single copy of KCNQ1OT1, and blue shows KCNQ1OT1 clusters. In this case, 753 epithelia 
cells were selected, which turned out to have an overall estimated 0.35 copies of KCNQ1OT1 per cell. 
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In this invasive breast cancer case, KCNQ1OT1 was stained as punctate singals in moderate to high 
intensity, with more than two copies per cell in less about 50-75% epithelia cells. Images were taken in 
10X objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same region [scale bar: 10 µm] 
 
Here, In this case, RNAscope® SpotStudio
TM 
software was used to analyze 1165 selected epithelia cells to 
have an overall estimated 1.83 copies of KCNQ1OT1 per cell. Images were taken in 10X objective lens 
(left) [scale bar: 20 µm] and 20X lens (right) for same region [scale bar: 10 µm] 
Figure 17. CISH stain of KCNQ1OT1 
 MEG3 
Similar to staining pattern of H19, MEG3 mainly localized in stromal cells around epithelia ducts 
as nuclear punctuate stain. 4/91(4%) cases with minor staining in epithelia cells were excluded in 
our study. Within TMAs probed with MEG3, 34 NA tissue spots, 23 DCIS tissue spots and 34 
invasive cancer spots were scored by eye by pathologist (DL). In MEG3, there were 14 patients 
having all three tissue types, 19 patients having NA and DICS tissues, 27 patients having NA and 
invasive cancer tissues and 18 cases keeping DCIS and invasive cancer tissues. The mean value 
of MEG3 score in NA tissue spots is 1.76 and the range was from 0 to 6:  0(n=21), 2(n=2), 3(n=3), 
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4(n=3), 5(n=1), 6(n=5). 21 cases with a score of zero were regarded as negative and from weak 
positive to strong positive, we had 2, 6 and 6 cases, respectively. In DCIS, we had fewer cases in 
each score (mean=1.3) and pattern: 0(n=14), 2(n=3), 3(n=2), 4(n=3), 6(n=1); negative (n=14), 
weak positive (n=3), moderate positive (n=5), strong positive (n=1). Among 34 cases of invasive 
cancer spots, 10 were scored 0 and regarded as negative; 2 were scored 2 and grouped as weak 
positive; 17 were scored 3 (n=4) or 4 (n=14) and grouped as moderate positive and last 2 cases 
were strong positive with a score of 5. The mean score of MEG3 in invasive spots was 1.7. Table 
10 shows MEG3 stain summary and figure 18 shows different MEG3 expression levels in terms 
of different scoring criteria. 
Table 10. Summary of MEG3 stain 
Tissue N mean stain grade Four tiered system Two tiered system 
   Neg W M S Low High 
NA 34 1.76 21 2 6 6 21 14 
DCIS 23 1.30 14 3 5 1 14 9 
IC 34 1.7 10 2 17 2 10 21 
















Negative stain of MEG3 on one NA breast case, image was taken with 10X objective lens 
[scale bar: 20 µm] 
 
 
Here, MEG3 was stained in moderate intensity in more than 75% stromal cells in invasive cancer spot. 
Images were taken in 10X objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same region 
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(C) shows that MEG3 was detected in 50-75% stromal cells, mainly in low stain intensity in DCIS. Images 





Images represent strong stain of MEG3 in more than 75% stromal cells in benign breast tissue. Images 
were taken in 10X objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same region [scale bar: 
10 µm] 
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MALAT1 was extensively and intensively stained in each cell across three different tissues.  We 
were unable to show any stain difference in MALAT1 and thus we were unable to test any 






MALAT1 was universally strongly stained on NA tissue (A), DCIS (B) and invasive cancer tissue (C). All 
images were photographed with 10X objective lens. [scale bar: 20 µm] 
Figure 19. Strong positive stain of MALAT1 
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Zfas1 stained like HOTAIR and KCNQ1OT1, which were punctate dots in epithelia cell nucleus. 
Although we saw some minor difference in stain proportion, the overall staining intensity was 
every low and overall score of cases were very close. So, we were unable to perform statistical 
analysis to demonstrate any significance in Zfas1. Figure 20 illustrates the generic staining 





Zfas1 was hardly seen in NA tissue (A); DCIS (B) and invasive cancer tissue(C). All images were taken 
with 20X objective lens. [scale bar: 10 µm] 
Figure 20. Faint stain of Zfas1 across TMAs 
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Long non-coding RNA associated protein staining results 
 EZH2 
Staining in epithelia cell nucleus, EZH2 was more prevalent in cancer cells rather than normal 
adjacent epithelia cells. Across our TMAs, we gave EZH2 score for 28 NA spots, 21 DCIS spots 
and 31 invasive spots. Among all patients, 10 individuals had all three tissue types available; 16 
individuals had both NA and DCIS spots; 16 individuals kept both NA and invasive cancer spots; 
15 individuals had DCIS and invasive cancer spots. In NA spots, most of cases (23/28) were 
scored as 0 and two cases were 1 and one case was 2, 3, and 4, respectively. Thus, we had 
negative pattern (n=23), weak positive (n=2) and moderate positive (n=2). In DCIS regions, 9 
cases were scored of zero and we had more score distributions: 1(n=2), 2(n=7), 4(n=1), 6(n=2). In 
regard to pattern, nine cases were grouped as negative, another nine cases were in weak positive, 
one case was in moderate positive and rest two cases were in strong positive. However, in 
invasive cancer spots, we had 15 cases as EZH2 negative while other scores include 1(n=4), 
2(n=4), 3(n=1), 4(n=3), 5(n=2), 6(n=2). Eight of them were in weak positive, four in moderate 
positive and three in strong positive. A summary of EZH2 stain is listed in Table 11. Figure 21 
shows different EZH2 expression levels according to different scoring criteria. 
Table 11. Summary of EZH2 
Tissue N mean stain 
grade 
Four tiered system Dichotomous scoring 
system 
   Neg W M S Low High 
NA 28 0.39 23 2 3  0 25 3 
DCIS 21 1.57 9 9 1 2 11 10 







Figure 21.  Different expressions of EZH2 across samples (A) Negative case of EZH2 in normal adjacent breast tissue; (B) EZH2 was found less than 10% epithelia cells 
with low stain intensity in benign breast tissue ;(C) EZH2 appeared in 50-75% epithelia cells in moderate intensity in invasive cancer; (D) Image shows EZH2 strong 
stain in more than 75% epithelia cells in DCIS (all images were taken with 10X lens) [scale bar: 20 µm]
         20µm 











         20µm 





CDKN1C was widely (>50%) and strongly stained in nucleus including epithelia, glandular and 
adipocyte cell nucleus in any NA spots and cancer spots, like what we found from MALAT1. 
Therefore, we were unable to show any statistical difference between each tissue type. Here, 
Figure 22 illustrates the generic staining format of CDKN1C. 
 
 
Figure 22. CDKN1C generic stain 
CDKN1C extensively expressed in nucleus with high intensity. Image was photographed with 10X lens 




Unlike CDKN1C, p53 was hardly stained in our TMAs. No p53 was found across all NA tissue 
spots. In our cancer spots, we found 10% (2/20) positive cases in DCIS and 6.3% (2/32) positive 
cases in invasive cancer. All positive cases had nuclear stain of p53, however, only one case 
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showing cytoplasmic staining was excluded in our study.  Both p53-positive and p53-negative 
cases are displayed in Figure 23. 
 
 
Figure 23. Positive and negative illustrations of p53 
(A) p53 positive in invasive cancer (B) p53 negative in NA breast, all images are in 10X objective lens 
[scale bar: 20 µm] 
 
 
Clinicopathological factors staining results 
Basic clinicpathological data was obtained from patient records. In our study, we confirmed ER, 
PR and Her2 status, explored Ki67 (MIB1) and E-cadherin status by doing 
immunohistochemistry on our TMAs. 
 Estrogen Receptor 
We dichotomized ER status in DCIS and invasive cancer spots. In DCIS regions, ER positive 
were found in 26/30 cases and the rest was all ER negative. In invasive cancer tissue, we had 
40/44 cases were ER positive and 4/44 were ER negative, which is in concord with the original 
patients information. ER staining illustrations are shown in Figure 24.  











Figure 24. Positive and negative illustrations of ER 
(A) ER negative (B) ER positive; Images were taken in 10X objective lens [scale bar: 20 µm] 
 
 Progesterone receptor(PR) 
PR status was tested in DCIS and invasive cancer tissues.  24 cases were found PR positive and 6 
cases were found PR negative in DCIS spots, while 36 spots were PR positive and 8 spots were 
PR negative in invasive cancer. Data collected from TMA staining perfectly matched previous 
clinical information. PR staining examples are shown in Figure 25. Hormone receptor statues 
were 26/30 positive in DCIS and 40/44 positive in invasive cancer. 
 
 
Figure 25. Positive and negative illustrations of PR 
(A) PR negative (B) PR positive; Images were taken in 10X objective lens [scale bar: 20 µm] 
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Her2 protein stained the membrane by IHC. In DCIS, there were no equivocal cases among all 16 
spots that was scored: 0(n=8), 1(n=5), 3(n=3), so only 3 cases were recorded as Her2 positive. In 
invasive spots, we scored 0 for 22 cases, 1 for 6 cases, 2 for 2 cases and 2 for 3 cases. After 
reconfirmation by dual in situ hybridization (one centromerical probe for chromosome 17  and 
one Her2 probe, performed in the FAHC lab), those 2 equivocal cases were grouped as Her2 
positive. In conclusion, 28 cases were Her2 negative and 4 were Her2 positive. Due to TMA 
construction issue, we missed several spots in our TMAs, resulting in fewer Her2 statues than 
original patient data, however, since all current TMA Her2 statues perfectly concords with 
original Her2 statues, we made up those missing data from original Her2 statue, resulting in an 
overall Her2 positive of 5 cases and Her2 negative of 38 cases. Figure 26 shows Her2 staining 













Figure 26. Examples of Her2 stain 
(A) Image shows Her2 negative case with a score of zero (B) image represents Her2 negative case with a score of one (C) Her2 positive with a score of 
three (D) Her2 equivocal case with a score of two by immunohistochemistry (E) Dual color CISH confirmed overexpression of Her2 in equivocal case. 
Image was taken with 10x objective lens in (A-D) [scale bar: 20 µm] and 20x objective lens (F) [scale bar: 20 µm]






          20µm 
          20µm 
          20µm 
       10µm 
80 
 
 Ki67 (MIB1)  
Ki67 protein was stained mostly as single or multiple dots, sometimes in clusters in epithelia cells. 
In DCIS spots, Ki67 protein was scored as 1(n=3), 2(n=5), 3(n=4), 4(n=6) based on percentage of 
cells that were stained. So, only those six cases with a score of 4 were recorded as Ki67 positive. 
In invasive cases, we found more Ki67 positive case with a score of 4 (13/35). Among the other 
22 cases which are Ki67 negative, 8 were scored 1, 10 were 2 and 4 were 3. Staining illustrations 
are shown in Figure 27. 
 
Figure 27. Illustrations of ki67 status 
(A) shows Ki67 negative because it only expressed in 5% cells (less than 15% threshold) (B) 
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E-cadherin was only stained in ductal carcinoma in situ or invasive ductal carcinoma, but 
negative in lobular carcinoma, shown in Figure.28. 
 




 Correlations between two independent scoring systems 
In order to demonstrate the data consistency between eye-based scoring system and RNAscope® 
SpotStudio
TM 
scoring software we used in for two lncRNA makers, HOTAIR and KCNQ1OT1, 
we used non-parametric Spearman rank correlation test to check the correlations (Table.12a and 
12b). In HOTAIR, significant correlations between two systems were found in DCIS and invasive 
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82 
 
Table 12. Spearman correlation study between two scoring systems 
a. Spearman correlation test for HOTAIR in all three tissue types 
Tissue type Sample size (n) Spearman’s rho Probabilities 
NA 26 0.339 0.067 
DCIS 25 0.497 <0.001 
IC 32 0.716 <0.0001 
 
b. Spearman correlation test for KCNQ1OT1 in all three tissue types 
Tissue type Sample size (n) Spearman’s rho Probabilities 
NA 30 0.749 <0.0001 
DCIS 25 0.681 <0.0001 
IC 32 0.769 <0.0001 
 
 
 Comparison of lncRNA expression across tissues 
To test our hypothesis that lncRNAs may express differently across tissue types, we applied non-
parametric Friedman two-way analysis of variance test on subjects containing all three tissue 
types. From the perspective of eye scoring system, HOTAIR, H19 and KCNQ1OT1 expressions 
are significantly different across tissues.  KCNQ1OT1 also has expression difference across our 
samples, while HOTAIR seems to have equal expression in different tissues in terms of score that 
produced by RNAscope® software (Table.13). Further paired comparison by same Friedman 
tests were applied only after overall tests was significant, resulting in more details upon different 
variables: the eye-determined expression levels of HOTAIR and H19 differs significantly in each 
paired comparison (Table.14a, Table.14b), however, both eye-determined and software 
determined KCNQ1OT1 score varies between normal adjacent and cancer, but not non-invasive 
and invasive (Table.14c).   
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Table 13. Non-parametric comparison for lncRNAs expression across tissues 











HOTAIR score 13.5 23.5 29.0 11 15.9 <0.001 
HOTAIR pattern 13.5 23.5 29.0 11 15.9 <0.001 
HOTAIR software 
 
17.5 21.0 27.5 11 4.9 0.086 
H19 score 27.0 34.5 52.5 19 25.0 <0.001 
H19 pattern 
 
27.5 34.0 52.5 19 25.4 <0.001 
KCNQ1OT1 
score 
11.5 22.0 26.5 10 13.5 0.001 
KCNQ1OT1 
pattern 




12.0 23.0 25.0 10 9.8 0.007 
MEG3 score 24.5 28.0 31.5 14 4.5 0.108 
MEG3 pattern 25.0 28.0 31.0 14 3.4 0.180 
Score represents the score was given by standard visual evaluation; pattern means the score was given by four tiered scoring system; software indicates 









Table 14. Non-parametric paired comparisons for lncRNAs 







b. Non-parametric paired comparison for H19 
 











H19 score 17.5 27.5 / 15 10.0 0.002 
 22.5 / 37.5 20 15.0 <0.001 
 / 22.0 29.0 17 7.0 0.008 
       
H19 pattern 17.5 27.5 / 15 10.0 0.002 
 22.5 / 37.5 20 15.0 <0.001 
















HOTAIR score 30.5 38.5 / 23 5.3 0.021 
 34.5 / 64.5 33 30.0 <0.001 
 / 23.0 37.0 20 12.3 <0.001 
       
HOTAIR pattern 30.5 38.5 / 23 5.3 0.021 
 35.0 / 64.0 33 29.0 <0.001 
 / 23.0 37.0 20 14.0 <0.001 
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c. Non-parametric paired comparison for KCNQ1OT1 











KCNQ1OT1 score 21.0 30.0 / 17 6.2 0.013 
 22.5 / 40.5 21 16.2 <0.001 
 / 21.0 27.0 16 3.6 0.058 
       
KCNQ1OT1 pattern 21.5 29.5 / 17 6.4 0.011 
 23.5 / 39.5 21 16.0 <0.001 




19.0 32.0 / 17 9.9 0.002 
 24.0 / 39.0 21 10.7 0.001 













 Association between lncRNA expressions and DCIS clinical markers 
We also tested the hypothesis that lncRNA expression may associate with DCIS clinical markers. 
Pearson correlation test was firstly conducted to screen potential correlations (Table 15). Here, 
we kept DCIS nuclear grade as initial report, which had five groups from 1 to 3. All potential 
correlations were further tested in non-parametric Kruskal-Wallis one-way ANOVA or Mann-
Whitney U test (Table 16a, 16b, 16c), suggesting multiple potential associations in HOTAIR and 
H19 were still valid,  but most associations determined by Pearson test in KCNQ1OT1 were 
incongruent with current methodology. (In Table 16a, 16b, 16c, KW represents Kruskal-Wallis 



































HOTAIR score / / / / 0.66(0.005) 0.50(0.036) / 
HOTAIR pattern / / / / 0.54(0.032) / / 
HOTAIR software / -0.83(<0.001) -0.49(0.014) -0.83(<0.001) / 0.58(0.011) / 
        
H19 score / / / / / 0.49(0.045) / 
H19 pattern / / / / / 0.53(0.03) / 
        
KCNQ1OT1 score 0.44(0.026) / / / / 0.51(0.029) / 
KCNQ1OT1 pattern 0.43(0.033) / / / / 0.51(0.029) / 
KCNQ1OT1 software / 0.56(0.004) / 0.56(0.004) / 0.48(0.044) 0.54(0.014) 
        
MEG3 score / / / / / / / 
MEG3 pattern / / / / / / / 











Table 16. Non-parametric Kruskal-Wallis test/ Mann-Whitney U test of lncRNAs in DCIS 
a. Non-parametric Kruskal-Wallis test/ Mann-Whitney U test of HOTAIR 
 sample size(n) KW/MW statistics Probabilities 
Score/Her2 16 1.5 0.013 
Score/Ki67 18 15.0 0.044 
    
Pattern/Her2 16 4.5 0.03 
    
Software/ER 25 46.0 0.021 
Software/PR 25 47.0 0.711 
Software/Hormone 25 46.0 0.021 
Software/Ki67 18 7.0 0.007 
 
b. Non-parametric Kruskal-Wallis test/ Mann-Whitney U test for H19 
 Sample Size(n) KW/MW statistics Probabilities 
Score/Ki67 17 14.0 0.045 
Pattern/Ki67 17 14.5 0.047 
 
c. Non-parametric Kruskal-Wallis test/ Mann-Whitney U test for KCNQ1OT1 
 Sample size (n) KW/MW statistics Probabilities 
Score/DCIS grade 25 7.0 0.072 
Score/Ki67 18 15.5 0.043 
    
Pattern/DCIS grade 25 7.4 0.06 
Pattern/Ki67 18 18.0 0.052 
    
Software/ER 25 39.0 0.109 
Software/Hormone 25 39.0 0.109 
Software/Ki67 18 17.0 0.075 
Software/p53 20 11.0 0.38 
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Besides non-parametric Kruskal-Wallis one-way ANOVA or Mann-Whitney U test that shows 
some associations between lncRNA expression level and DCIS clinical markers according to 
statistical difference in mean, we also applied Fisher’s exact test to demonstrate associations 
between lncRNA expression and clinical markers in terms of different frequency.  Here, we 
performed all tests on dichotomized number for both lncRNA expression level and clinical 
markers in order to provide us with more significant correlations and more understandable 
interpretations based on our sample size. All the fisher’s exact tests were done by 2x2 
contingency table. (Table 17) 
 
Table 17. Association study between dichotomous lncRNA level and clinical markers in DCIS by 
Fisher’s exact test 
Clinical item lncRNA Sample size Fisher’s exact test value Odds Ratio 
DCIS grade HOTAIR 25 0.294 ∞ 
 H19 25 0.661 0.476 
 KCNQ1OT1 25 0.294 ∞ 
 MEG3 23 0.657 0.514 
ER HOTAIR 25 1.00 0 
 H19 25 0.507 ∞ 
 KCNQ1OT1 25 1.00 0 
 MEG3 23 0.142 0 
PR HOTAIR 25 0.527 2.00 
 H19 25 0.140 ∞ 
 KCNQ1OT1 25 1.00 0 
 MEG3 23 1.00 0.583 
Her2 HOTAIR 16 1.00 ∞ 
 H19 15 1.00 1.50 
 KCNQ1OT1 16 1.00 ∞ 
 MEG3 16 1.00 2.333 
Ki67 HOTAIR 18 0.515 ∞ 
 H19 17 0.280 4.50 
 KCNQ1OT1 18 0.515 ∞ 
 MEG3 18 0.620 2.80 
P53 HOTAIR 20 1.00 ∞ 
 H19 19 1.00 2.40 
 KCNQ1OT1 20 1.00 ∞ 






 Association between lncRNA expressions and invasive clinical markers 
Subsequently, we applied same working procedures to determine the hypothesis that lncRNA 
expression may associate with invasive clinical markers. Pearson correlation test was firstly used 
as screen tool (Table 18) and non-parametric Kruskal-Wallis one-way ANOVA or Mann-
Whitney U test were applied to validate candidate associations (Table 19a, 19b, 19c). In this test, 
Nottingham score remained from 4 to 9 and tumor size were trichotomized. (In table 10a, 10b, 
10c, KW represents Kruskal-Wallis test that was used for groups > 3, MW indicates Mann-









































HOTAIR score 0.35(0.049) 0.40(0.023) / / / / / / 0.4(0.04) / 
HOTAIR pattern 0.37(0.037) 0.40(0.023) / / / / / 0.37(0.039) 0.37(0.041) / 
HOTAIR software 0.35(0.050) 0.37(0.036) / -0.53(0.002) / -0.53(0.002) 0.53(0.002) 0.07(0.001) / / 
        / / / 
H19 score / / / / / / / / / / 
H19 pattern / / / / / / / / / / 
        / / / 
KCNQ1OT1 score 0.41(0.02) / / / / / / / / / 
KCNQ1OT1 pattern 0.51(0.003) / / / -0.36(0.042) / / 0.39(0.027) / / 






/ / / / 
        / / / 
MEG3 score / / / / / / / / / / 
MEG3 pattern / / / / / / / 0.38(0.027) / / 







Table 19. Non-parametric Kruskal-Wallis test/ Mann-Whitney U test of lncRNAs in invasive 
cancer 





















c. non-parametric Kruskal-Wallis test/ Mann-Whitney U test for MEG3 
 
 sample size(n) KW/MW statistics Probabilities 
Score/Nottingham 32 6.9 0.231 
Score/tumor size 32 5.1 0.077 
Score/Ki67 status 31 58.5 0.019 
    
Pattern/Nottingham 32 7.1 0.215 
Pattern/tumor size 32 5.1 0.078 
Pattern/Her2 32 30.0 0.032 
Pattern/Ki67 31 67.5 0.039 
    
Software/Nottingham 32 4.9 0.431 
Software/tumor size 32 4.4 0.112 
Software/ER 32 31.0 0.938 
Software/hormone 32 60.0 0.019 
Software/triple N 32 29.0 0.938 
Software/Her2 32 13.0 0.005 
 sample size(n) KW/MW statistics Probabilities 
Score/Nottingham 32 6.4 0.267 
    
Pattern/Nottingham 32 10.2 0.071 
Pattern/PR 32 103.0 0.05 
Pattern/Her2 32 20.5 0.032 
    
Software/Nottingham 32 5.0 0.415 
Software/ER 32 60.0 0.019 
Software/PR 32 125.5 0.003 
Software/hormone 32 60.0 0.019 
 sample size (n) KW/MW statistics P 
Pattern/Her2 34 30.5 0.026 
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Similarly, we test whether lncRNAs are associated with clinical makers regarding frequency by 
using Fisher’s exact test. We also performed all tests on dichotomized number for both lncRNA 
expression level and clinical markers except invasive histological grade, which was analyzed 
non-parametric spearman rank correlation test.  All the fisher’s exact tests were done by Pearson 























Table 20. Association study between dichotomized lncRNA level and clinical markers in invasive 
cancer by Fisher’s exact test 
clinical items lncRNA sample size Fisher’s exact test 
value 
Odd ratio 
Tumor size HOTAIR 32 0.069 ∞ 
 H19 35 0.297 ∞ 
 KCNQ1OT1 32 0.550 ∞ 
 MEG3 34 0.683 2.00 
Lymph node HOTAIR 28 0.128 ∞ 
 H19 31 0.147 ∞ 
 KCNQ1OT1 28 0.295 ∞ 
 MEG3 29 0.107 6.55 
LVI HOTAIR 32 0.025 ∞ 
 H19 35 0.630 2.667 
 KCNQ1OT1 32 0.272 ∞ 
 MEG3 34 0.251 3.385 
ER HOTAIR 32 1.000 0 
 H19 35 0.477 2.250 
 KCNQ1OT1 32 1.000 0 
 MEG3 34 1.000 0 
PR HOTAIR 32 1.000 .667 
 H19 35 0.568 2.667 
 KCNQ1OT1 32 1.000 0 
 MEG3 34 0.644 0.422 
Triple negative HOTAIR 32 1.000 ∞ 
 H19 35 0.477 0.444 
 KCNQ1OT1 32 1.000 ∞ 
 MEG3 34 1.000 ∞ 
Her2 HOTAIR 32 0.560 ∞ 
 H19 35 1.000 ∞ 
 KCNQ1OT1 32 1.000 ∞ 
 MEG3 34 0.291 ∞ 
Ki67 HOTAIR 31 0.201 5.077 
 H19 34 1.000 2.000 
 KCNQ1OT1 31 0.601 0.500 
 MEG3 32 1.000 1.286 
P53 HOTAIR 31 0.406 0.261 
 H19 32 1.000 ∞ 
 KCNQ1OT1 30 1.000 ∞ 
 MEG3 32 1.000 ∞ 







Table 21. Association study between dichotomized lncRNA level and invasive histological grade 
in invasive cancer by Spearman rank correlation test 
Clinical item lncRNA sample size Spearman Rho Probabilities 
Histological grade HOTAIR 32 0.375 0.026 
 H19 35 0.090 0.583 
 KCNQ1OT1 32 0.071 0.719 
 MEG3 34 0.168 0.271 
Probabilities are two-tailed 
 
 Logistic regression analysis for lncRNA to predict cancer aggressiveness 
As we already noticed some associations between lncRNA expression level and clinical markers 
by either Kruskal-Wallis one-way ANOVA test or Fisher’s exact test, we subsequently tested the 
hypothesis that lncRNAs combined clinical items status can better predict DCIS or invasive 
cancer grade. First of all, we used Fisher’s exact test on dichotomized dataset to look for 
associations between DCIS nuclear grade and all other markers (Table 22a), and we also applied 
Spearman rank correlation study to check any correlation between trichotomized invasive 
histological grade and the other markers (Table 22b). From our analysis, we did not find any 
significant correlation between DCIS nuclear grade and lncRNAs, but ER (p=0.012). However, 
since there was only one variable suggesting association, we did not perform multivariate test. In 
invasive cancer subjects, multiple variables have been found correlation with histological grade, 
including HOTAIR (p=0.026), ER (p<0.001, negative relationship), triple negative (p<0.001) and 
Ki67 (p<0.001). Then we provided multivariate logistic regression to test the predictability of 







Table 22. Correlation test of cancer grade and all markers 
a. Correlation test for DCIS nuclear grade by Fisher’s exact test 
Variable 1 Variable 2 Sample size Fisher’s exact test value 
DCIS nuclear grade HOTAIR 25 0.294 
 H19 25 0.661 
 KCNQ1OT1 25 0.294 
 MEG3 23 0.657 
 ER 30 0.012 
 PR 30 0.156 
 Her2 16 0.518 
 Ki67 18 0.107 
 P53 20 0.521 
 
 
b. Correlation test for invasive histological grade by Spearman rank correlation test 
Variable 1 Variable 2 Sample size Probabilities 
Invasive histological grade HOTAIR 32 0.026 
 H19 35 0.582 
 KCNQ1OT1 32 0.719 
 MEG3 34 0.271 
 Tumor size 44 0.234 
 Lymph node 38 0.517 
 LVI 44 0.739 
 ER 44 <0.001(negative) 
 PR 44 0.082 
 Triple negative 44 <0.001 
 Her2 43 0.155 
 Ki67 35 <0.001 
 P53 33 0.138 
 
Binary logit analysis was chosen because we dichotomized histological grades as our limited 
sample size. Firstly, we categorized invasive histological grade into low grade (n=8) coded with 0 
and non-low grade (n=19) coded with 1.  We took the first step to consider bivariate logistical 
regression, using dichotomized histological grade as criterion variable and lncRNA expression 
level as dichotomous predictor variable. Our regression model will be predicting the logit, that is, 
the natural log of the odds of having one or the other histological grade (model is shown below), 
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where Y was the probability of the event which is coded with 1, 1-Y was the predicted probability 
of the event coded with 0, and X was the predictor variable, lncRNA dichotomized score. 
         
 
   
       
Our data suggests only HOTAIR (p=0.011) was a positive predictor among all lncRNAs and odds 
ratio was 14.167. Our regression equation is                     . 
Then, we applied same binary logit analysis on all dichotomized clinical items. However, it 
turned out that no clinical items was a good predictor.  Lastly, we performed a multivariate 
logistical regression to take both dichotomous lncRNA expression and clinical items into account. 
We set up another model to predict odds as shown below, where Y was the probability of the 
event which is coded with 1, 1-Y was the predicted probability of the event coded with 0, and Xn 
was a single predictor variable, lncRNA or clinical item 
         
 
   
                 
Only lymphovascular invasion (LVI) status (p=0.08) and HOTAIR (p=0.043) showed a joint 
ability to predict cancer grade with an odds ratio 16.5. Our equation is               
               , where X1 represents lymphovascular invasion status and X2 represents 
HOTAIR. 
Similarly, we categorized invasive histological grade into high grade (n=6) coded with1 and non-
high grade (n=21) coded with 0. However, we could only find Ki67 status is a good predictor 





 Correlation between protein markers and lncRNA expression 
Functionally, one mechanism of lncRNAs influencing gene expression is to recruit epigenetic 
protein factors to regulate chromatin states of target gene in cis or trans. Polycomb repressive 
complex 2, (PRC2), as a chromatin-modifying complex, interacts with a large group of lncRNA 
including HOTAIR, H19 and KCNQ1OT1.  From our study, we found EZH2 significantly 
expressed higher in cancer than in NA breast tissue (p<0.001)  Here, we tested the hypothesis that 
the expression of Enhancer of zeste homolog 2 (EZH2), as a key protein member of PRC2 
complex as gene silencer, increases as lncRNAs express, by Pearson correlation study (Table 23). 
Our data suggests only one correlation between KCNQ1OT1 expression and EZH2 expression in 
invasive cancer (p=0.006). 








NA EZH2 HOTAIR 23 0.034 0.877 
  H19 26 0.272 0.179 
  KCNQ1OT1 25 -0.007 0.972 
DCIS EZH2 HOTAIR 21 0.294 0.197 
  H19 21 0.371 0.098 
  KCNQ1OT1 21 0.065 0.781 
IC EZH2 HOTAIR 29 -0.085 0.662 
  H19 31 0.016 0.993 










RNAscope® in situ hybridization assay 
Regarding the work platform, RNAscope in situ hybridization technology has now been 
employed elsewhere to detect lncRNA (Bao, Wu et al. 2013 [male mouse germline]; Prensner, 
Iyer et al. 2013 [prostate cancer]; Warrick, Tomlins et al. 2014 [prostate cancer]), providing 
valuable information on clinical relevant information upon cellular and tissue context that is 
unable to visualize by routine microarray and quantitative PCR.  The present study demonstrates 
the quality and specificity of RNAscope technology to detect lncRNA on FFPE tissues. 
Sample size 
In current study, tissue microarray was manufactured to provide a standard and high throughput 
assays on same tissue source for both RNA candidate markers and immunohistochemical markers 
with comparatively low cost. Although routine H&E slides were made from selected FFPE blocks 
to help pathologists to mark concurrent developed DCIS, invasive cancer and adjacent normal 
tissue regions that would be included in TMAs, mixed tissue areas were accidentally found on our 
TMA slides after we rescreened TMA slides with H&E slides for confirmation. In that case, we 
only reviewed tissue piece that was intended to be there. As breast tissue contains most abundant 
adipocytes, 8 of 44 (18%) normal adjacent spots turned out to only have adipose tissue so that 
they were excluded for further analysis. We had the least number of DCIS spots (n=34) across 
our TMAs because of two reasons: 1) several patients only had NA and invasive cancer tissues 2) 
several spots contained very little DCIS part that was easily removed during manufacturing 
process.  Comparing with NA and DCIS tissue, we kept the most number (n=44) of invasive 
cancer tissue source. However, we ended up having fewer tissue spots on our TMAs to score and 
analyze because some more spots were washed away during multiple pretreatment and 






Our results suggest lncRNAs have different staining patterns, mostly in concord with previous 
publications. The HOTAIR RNA probe stained predominately as single or multiple dots that was 
widely present in all three tissue sources (Chisholm, Wan et al. 2012 [digoxigenin-labeled 
riboprobe ISH]). However, most signals were found in nucleus with some scattered dots in 
cytoplasm, contrary to what Chisholm, et al. found in their paper, which suggests HOTAIR was 
more prevalent in cytoplasm (Chisholm, Wan et al. 2012). As their primary focus on metastatic 
breast carcinoma while we were looking at primary tumors, it is possible that HOTAIR escapes 
from nucleus to cytoplasm as primary tumor metastases. Our data also provides us some evidence 
that HOTAIR expresses at different levels across different types of tissue. Generally HOTAIR 
signal enhances as cancer aggressiveness increases. Friedman two-way analysis of variance test 
shows HOTAIR has significantly higher expression in cancer cells than normal adjacent epithelia 
cells (p<0.001). Even within cancer spots, invasive cancer is more aggressive and has more 
intense HOTAIR score than that of DCIS (p=0.021). 
KCNQ1OT1 
Prior studies have used fluorescent in situ hybridization (FISH) to visualize KCNQ1OT1 signal in 
nucleus of both human and mouse cells (Mohammad, Pandey et al. 2008; Korostowski, Sedlak et 
al. 2012). This is the first study to localize KCNQ1OT1 as punctuate dots in cell nucleus on FFPE 
tissue samples by CISH. Comparing with HOTAIR, KCNQ1OT1 is not that popular in terms of 
staining grade. Across our tissue microarray, we have 5 negative cases without any stain of 
KCNQ1OT1, most of which (4/5) are normal adjacent tissue spots, suggesting KCNQ1OT1 may 
express more frequently in cancer spots as a candidate oncogene. Also, there is an increased 
KCNQ1OT1 expression in regard to KCNQ1OT score in cancers than in NA (p=0.013). However, 
we did not notice any statistical difference of KCNQ1OT1 expression between non-invasive 
DCIS tissue and more malignant invasive cancer spots (p=0.058), revealing some possibilities 
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that KCNQ1OT1 is triggered by some pre-cancer events and then keep expressing as cancer 
develops. 
H19 
As an important oncogene for tumor growth, H19 was first detected in hepatocellular carcinoma 
by both radioactive and non-radioactive riboprobe in situ hybridization (Ariel, Miao et al. 1998). 
The present study provides some insights to localize H19 in breast carcinoma by RNAscope 
CISH. H19 was stained more diffusely and intense in cancer, compared with normal adjacet spots 
that usually negative or focal expression (p<0.001), strikingly, H19 also expressed significantly 
higher in more malignant invasive cancer than in DCIS (p=0.008). In this study, we also found 
that H19 appeared primarily in stromal cells of breast tissue especially at the boundary of breast 
cancer ducts as also reported by Ariel and his colleagues in 1998. However, other studies have 
also found H19 stained in epithelia ovarian cancer cells and bladder cancer cells (Mizrahi, 
Czerniak et al. 2009; Amit and Hochberg 2010). Together with current research focus on exsomes 
guided tumorigenesis and the fact lncRNAs has been found in exosomes by deep sequencing 
(Huang, Yuan et al. 2013), it may give rise to additional research to investigate H19 and tumor 
microenvironment. 
MEG3 
Similar to H19, our image depicts that MEG3 stained in stromal cell nucleus around breast ducts, 
which is the first study to visualize MEG3 RNA molecule on breast tissue. Our results compared 
MEG expression in each tissue types and found there was no significance between tissue types 
(p=0.108), while previous study showed MEG3 was lost in human breast cancer cell line MCF-7 
and thus proposed MEG3 might be a novel tumor suppressor (Zhang, Zhou et al. 2003). This 
contradiction may be because of much more complexity and chaos in real human tissue than pure 
cell line, which would turn out to have different conclusions. Other than staining stromal cells, 
MEG3 has also been found previously to localize in most normal pituitary cells (Gejman, Batista 
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et al. 2008) and in cytoplasm of non-neoplastic liver cells(Braconi, Kogure et al. 2011), indicating 
MEG3 might be involved in a spectrum of cell activity with different functionalities.  
MALAT1 
As a key regulator in lung cancer, MALAT1 was implicated to play an oncogenic role and 
upregulation of MALAT1 was also observed in several other cancers, including breast cancer 
(Lin, Maeda et al. 2007). On the contrary, our results exhibited a universal strong nuclear stain of 
MALAT1 for every tissue spots of our tissue microarray slides. However, the reason that results 
in contradictory results is largely unknown, leading us to investigate both expressional and 
functional perspectives of MALAT1 in breast cancer in more details. 
Zfas1 
One Snord-host long noncoding RNA Zfas1, has been suggested detected by chromogenic in situ 
hybridization in mice pregnant mammary gland epithelia cells and the paper also evidenced that 
Zfas1 might be a breast cancer tumor suppressor by showing relatively lower expression level of 
Zfas1 in human breast cancer than in normal by quantitative PCR (Askarian-Amiri, Crawford et 
al. 2011).  Current study on Zfas1 depicted a similar Zfas1 staining pattern as previous study 
showed, both of which were stained as low intensity dots in epithelia cell nucleus. Nonetheless, in 
order to assign them scores, even experienced pathologists had trouble to tell the minor difference 
between subjects so we did not review Zfas1 as carefully as other lncRNAs in order to prevent 
scoring bias. In situ hybridization assay, together with quantitative PCR or advanced quantitative 
image software, would be the best choice to further analyze Zfas1. 
LncRNA and EZH2 
EZH2, a key subunit of polycomb repressive complex 2 that is usually interacts with lncRNA, has 
been extensively associated with lncRNA, especially HOTAIR, H19 and KCNQ1OT1(Gupta, 
Shah et al. 2010; Luo, Li et al. 2013; Zhang, Zeitz et al. 2014). In this study, using 
immunohistochemistry to assess EZH2 expression level, we found an increase expression of 
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EZH2 in cancer than NA tissue (p=0.003), however, there was no difference of EZH2 between 
DCIS tissue and invasive cancer tissue (p>0.05). We did not find any correlation between EZH2 
and lncRNAs in either NA or DCIS tissue, however, we noticed only one strong correlation 
(p=0.006) between EZH2 and KCNQ1OT1 in invasive tissue. Although whether H19 or 
KCNQ1OT1 induce EZH2 is largely unknown, Chisholm’s paper showed HOTAIR and EZH2 
are co-expressed in breast cancer. Because of our limited sample size, we might not be able to 
confirm some correlations, but we still provided some evidence for co-expression of KCNQ1OT1 
and EZH2 in invasive breast cancer. 
Clinicopathological correlations 
In the present study, by using Pearson correlation test and non-parametric ANOVA test, we found 
HOTAIR positively trends trend with Her2 (p=0.013) and Ki67 (p=0.044), H19 positively 
correlates with Ki67 (p=0.045) in DCIS. Interestingly, only one true correlation between 
KCNQ1OT1 and clinicopathological factors, which was Ki67, was identified (p=0.043) although 
our screening Pearson test proposed multiple associations, indicating Pearson test is not robust 
when one variable is categorical. With invasive clinicopathological factors, only HOTAIR 
significantly associates with Ki67 (p=0.019). However, by performing same test by using three-
tiered score of lncRNAs as a filter, we could find more robust associations, for example, in DCIS, 
HOTAIR only significantly correlated with Her2 (p=0. 03) and H19 positively associates with 
Ki67 (p=0.047); in invasive cancer, HOTAIR highly associates with Her2 (p=0.032) and Ki67 
(p=0.039), KCNQ1OT1 positively correlates with Her2 (p=0.032) and negatively marginal 
correlates with PR positivity (p=0.05) , providing more important insights for clinicopathological 
correlations. By using univariate analysis on our dichotomous data, we were able to find a 
significant positive association between HOTAIR and histological grade (p=0.011) with odds 
ratio of 14.167. Our regression equation is                      , indicating the odds is 
5.668 if this subject has high expressed HOTAIR and odds is 0.4 if this case has low HOTAIR 
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expression level. We subsequently converted odds to probabilities, resulting in a probability of 
0.85 with predictor variable coded with 1, but a probability of 0.29 with predictor variable coded 
with 0, indicating our model can predict 85% HOTAIR high expression (coded with 1) will have 
non-low grade invasive breast cancer (coded with 1), while this model can predict only 29% cases 
with higher HOTAIR expression will have non-low grade cancer, also suggesting HOTAIR is an 
informative independent prognostic factor for invasive cancer aggressiveness. Previous studies 
have already reported HOTAIR highly associated with primary tumor grade in colorectal cancer, 
epithelia ovarian cancer and gastric cancer, and we confirm it in primary breast tumor (Kogo, 
Shimamura et al. 2011; Emadi-Andani, Nikpour et al. 2014; Qiu, Lin et al. 2014). Subsequent 
multivariate analysis suggested the combination of lymphovascular invasion and HOTAIR 
expression was able to result in better prediction for histological grade with an odds ratio of 16.5. 
Our equation is                              , where X1 represents 
lymphovascular invasion status and X2 represents HOTAIR.  As we can notice that HOTAIR 
positively relates with odds while LVI status had a negative relationship with odds in our model. 
The odds is 11 when the case presents LVI negative while has highly expressed HOTAIR, 
resulting in a probability of 0.92, which indicates our model predicts that 92% of cases with LVI 
negative and high HOTAIR  status will have a more aggressive cancer. However, the odds is 0.08 
for cases that have both positive LVI and low HOTAIR expression.  The probability is 0.07, 
indicating that our model predicts only 7% of patients who have been found with low HOTAIR 
and positive LVI, will eventually have a cancer beyond low histological grade. Although 
currently standard H&E staining is an easy and informative approach for grading cancer, 
HOTAIR also may be a useful adjunct test for the evaluation of equivocal grades. We also found 
a few cases that deviated from the trend, i.e., low HOTAIR expression in high-grade tumors: this 
type of dysregulation in invasive cancer might represent a specific subgroup of invasive cancers; 
further HOTAIR studies are required. As all the comparisons in this study were tested between 
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DCIS, invasive tissue and normal adjacent tissue, further studies are also required comparing 





Manual scoring is time consuming and prone to subjectivity and poor reproducibility, however,  
RNAscope SpotStudio
TM 
software is an intuitive automated system that is designed specifically 
for RNAscope technology for quantification. Generally, it quantifies signal intensity and area in 
single molecule sensitivity. This present study also utilized this software package for HOTAIR 
and KCNQ1OT1 as an adjunct quantification because their signal are mostly dots rather than 
whole nucleus stain of MEG3 or “streak” stain around ducts boundary of H19. Significant 
correlations between eye-scored lncRNA expression level and software-scored lncRNA 
expression level were both found in HOTAIR and KCNQ1OT1 across different tissue types, with 
an exception of HOTAIR in NA tissue. However, we found some inconsistent results when we 
used software generated results for tissue comparison study and clinicopathological correlations 
study, largely because there were a few extreme observations identified by SpotStudio
TM 
that 
increase too much variability. Although image analysis tool prone to provide standard 
quantification, it also requires operator to manually select regions of interest, optimize nucleus 
diameter and hematoxylin stain parameter that also might result in subjectivity. Moreover, strong 
hematoxylin stain is very likely to perplex this image analysis system in recognition of true 
signals. And more than that, too much variation has been observed in our limited samples so that 





The primary goal of this research was to detect lncRNA molecules in FFPE specimens and test 
for associations between lncRNA expression and clinicopathological factors. From our results, 
we conclude that the RNAscope® CISH assay is a highly effective tool for visualizing lncRNA 
expression. With this novel technology, we can not only quantify RNA expression to single copy 
sensitivity, but also visualize RNA molecules and interpret their expression within the cellular 
context, which is not possible by qPCR. Regarding the expression level of lncRNA across tissues, 
we can conclude that oncogenic activity of HOTAIR, H19 and KCNQ1OT1 is demonstrated in 
breast cancer by showing that all of them have significantly higher expression levels in cancer 
tissue than normal adjacent. Also, both HOTAIR and H19 express significantly higher in invasive 
cancer than non-invasive ductal carcinoma in situ. Moreover, some associations between lncRNA 
and clinical items are suggested by the current investigation. HOTAIR was found to associate 
with Her2 status in both DCIS and invasive cancer. HOTAIR was also concluded to be a critical 
independent positive predictor for invasive cancer histological grade. The other two important 
lncRNAs, KCNQ1OT1 and H19, were also found to correlate with some important clinical 
factors. Although this study did not directly address the causal mechanisms by which lncRNA 
aberrant expression relates to clinical status, it can be hypothesized on the basis of other 
functional studies that lncRNAs participate in a spectrum of cell activities and that lncRNA 
dysregulation promotes or attenuates tumor development. We also concluded that the use of 
image analysis software facilitates standardized RNAscope data interpretation. 
Project Summary and Future Direction 
 
Both projects examined novel approaches for assessing biomarkers of breast carcinoma. The 
perspectives are different: in the first study, we focused on tumor cell DNA content, which has 
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previously been shown to have an association with breast cancer clinical and pathological 
characteristics. Here, we developed an alternative technique for DNA content analysis by flow 
cytometric analysis and show the utility of our novel tissue core sampling approach for measuring 
DNA content in FFPE tissue specimens. Strikingly, we also found this alternative tissue sampling 
method is a good approach for the intratumoral heterogeneity assay of solid breast tumors. Future 
investigations would apply multiparametric approaches that combined DNA content, protein 
markers labeling, and chromosomal changes to better identify distinct groups in breast carcinoma. 
Moreover, future studies would be also able to utilize the proposed technique and single cell 
sequencing to obtain a better understanding of the composition of tumors, and the significance for 
prognosis and even personalized therapeutics.  
In the second study, lncRNAs that may be biomarkers for both invasive breast cancer and DCIS 
were examined by using RNAscope® CISH. We visualized and quantified lncRNA stains by 
bright field microscopy. Several associations between lncRNAs and clinicopathlogical factors 
have been found, suggesting potential utility of lncRNA CISH in breast carcinoma diagnostics. 
Future studies require an increased sample size. A small sample size might cause too much 
deviation that result in spurious correlations. With the help of the RNAscope CISH assay in 
combination with TMAs, more and more lncRNAs probes can be designed and tested on either 
preserved tissue of fresh tissue.  Automated RNAscope CISH is also now possible supporting 
high-throughput standardized research and clinical assays that can be combined with the 
advanced semi-quantitative software supporting data analyses uncompromised by human 
subjectivity. As we point out some associations already, functional studies would be another 
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